modafinil has been researched along with Fatigue in 168 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether armodafinil reduces fatigue in patients with HGG and moderate-to-severe fatigue." | 9.51 | Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial. ( Brown, PD; Cerhan, JL; Jaeckle, KA; Kizilbash, SH; Kohli, S; Le-Rademacher, J; Liu, H; Loprinzi, CL; McMurray, RP; Mehta, MP; Porter, AB; Sloan, J; Villano, JL, 2022) |
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 9.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "The aim of this study was to compare the efficacy and safety of modafinil and dexamethasone in the management of cancer-related fatigue and their effects on quality of life (QoL)." | 9.41 | Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Deb, U; Mukhopadhyay, S, 2021) |
| " Eligible participants with MS and significant fatigue severity are randomly assigned (1:1:1) to received either CBT, modafinil, or a combination of CBT and modafinil for 12 weeks." | 9.30 | A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the "COMBO-MS" trial. ( Alschuler, KN; Braley, TJ; Ehde, DM; Kratz, AL; Kulkarni, S; Little, R; Pickup, K; von Geldern, G, 2019) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 9.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "This pilot study, the first double-blind, placebo-controlled trial assessing whether a wake-promoting therapy can improve residual daytime sleepiness in patients with treated nocturia, indicates the promise of armodafinil for addressing this residual sleepiness and provides impetus to carry out a large-scale study to definitively evaluate whether armodafinil is an effective therapy for the many patients with nocturia who experience daytime sleepiness that persists, despite their receiving standard therapy for this condition." | 9.24 | Double-Blind, Placebo-Controlled, Crossover Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia. ( Krystal, AD; Preud'homme, XA, 2017) |
| "This study aimed to assess the efficacy of modafinil, a wakefulness-promoting agent in alleviating post-stroke fatigue ≥3 months after stroke." | 9.24 | MIDAS (Modafinil in Debilitating Fatigue After Stroke): A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial. ( Attia, J; Bivard, A; Holliday, E; Krishnamurthy, V; Levi, CR; Lillicrap, T; Nilsson, M; Pagram, H; Parsons, M, 2017) |
| "This study aims to obtain preliminary data on the efficacy of armodafinil for improving menopause-related fatigue and quality of life." | 9.22 | Armodafinil for fatigue associated with menopause: an open-label trial. ( Barsky, M; Cohen, L; Freeman, MP; Galvan, T; Joffe, H; Kim, S; Meyer, F; Petrillo, L, 2016) |
| "To evaluate the impact of modafinil on "free" and "cued" recall of clinical information in fatigued but nonsleep-deprived clinicians." | 9.22 | Structured cues or modafinil for fatigue amelioration in clinicians? A double-blind, randomized controlled trial of critical clinical information recall in fatigued clinicians. ( Darzi, A; Flindall, I; Goodship, J; Leff, DR; Sugden, C, 2016) |
| "CBT-I with and without armodafinil resulted in a clinically and statistically significant reduction of subjective daytime fatigue in cancer survivors with chronic insomnia." | 9.22 | Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Hoefler, J; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Shayne, M, 2016) |
| "To assess the efficacy of modafinil for the treatment of new learning and memory deficits and fatigue in multiple sclerosis." | 9.22 | Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial. ( Chiaravalloti, ND; DeLuca, J; Elovic, E; Ford-Johnson, L; Lengenfelder, J; Zhang, J, 2016) |
| "The aim of this study was to examine the effect of modafinil on depression via a secondary data analysis of a randomized clinical trial of modafinil for fatigue in cancer patients." | 9.22 | Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy. ( Conley, CC; Dakhil, S; Gross, H; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Scalzo, AJ, 2016) |
| "While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study." | 9.22 | A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. ( Alexander, BM; Arvold, ND; Doherty, L; Drappatz, J; Fadul, CE; Gaffey, SC; Hammond, S; Kesari, S; LaFrankie, D; Lee, EQ; Muzikansky, A; Nayak, L; Norden, AD; Pulverenti, J; Reardon, DA; Rinne, ML; Ruland, SF; Smith, KH; Stefanik, J; Wen, PY; Wong, ET, 2016) |
| "MIDAS is a phase II, single-centre, prospective, double-blinded, randomised, crossover trial of modafinil for the treatment of persistent fatigue in survivors of ischaemic stroke." | 9.22 | Modafinil In Debilitating fatigue After Stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial. ( Attia, J; Bivard, A; Krishnamurthy, V; Levi, CR; Lillicrap, T; Nilsson, M; Parsons, MW, 2016) |
| "This double-blind, placebo-controlled phase 3 trial evaluated the efficacy of armodafinil in MM patients with evidence of moderate fatigue." | 9.20 | A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. ( Andreu-Vieyra, C; Berenson, JR; Charu, V; Chen, CS; Nassir, Y; Sanani, S; Schlutz, M; Shamasunder, HK; Swift, RA; Vescio, R; Woliver, TB; Yellin, O, 2015) |
| "A phase II, multi-institutional, placebo-controlled randomized trial assessed feasibility of armodafinil 150 mg/day in participants receiving brain RT, from whom we obtained estimates of variability for fatigue, sleepiness, QOL, cognitive function, and treatment effect." | 9.20 | Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. ( Bryant, D; Case, D; Chan, MD; Grisell, D; Lesser, GJ; Lu, L; Monitto, DC; Naughton, MJ; Page, BR; Rapp, SR; Savona, SR; Shah, S; Shaw, EG, 2015) |
| "One thousand one hundred twenty-one patients with stroke were screened and 41 patients included, 21 received modafinil." | 9.20 | Modafinil May Alleviate Poststroke Fatigue: A Randomized, Placebo-Controlled, Double-Blinded Trial. ( Damgaard, B; Overgaard, K; Poulsen, MB; Rasmussen, RS; Zerahn, B, 2015) |
| "This multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy of modafinil in patients with metastatic prostate or breast cancer undergoing docetaxel chemotherapy (every 21 days; minimum dose 50 mg/m(2))." | 9.19 | Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. ( Abdi, E; Bonaventura, A; Craft, P; de Souza, P; Hill, A; Hovey, E; Lloyd, A; Marx, G; Michele, A; Parente, P; Rapke, T, 2014) |
| "Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting." | 9.19 | Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. ( Bahadori, R; Bates, N; Benepal, T; Blackhall, F; Dutton, S; Fife, K; O'Brien, M; Spathis, A; Stone, P; Wee, B; Wharton, R, 2014) |
| " Relative to baseline, patients reported lower fatigue severity (CIS) and better motivation (CIS) in both the modafinil (P = ." | 9.17 | The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. ( Boele, FW; Cleijne, W; de Groot, M; Douw, L; Heimans, JJ; Klein, M; Reijneveld, JC; Taphoorn, MJ; van Thuijl, HF, 2013) |
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 9.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "This was a double-blind, placebo-controlled, crossover study of sarcoidosis patients followed up in one sarcoidosis clinic Sarcoidosis patients with fatigue received either armodafinil or placebo with eight weeks of therapy for each arm and a two week washout period before crossover to the other treatment." | 9.17 | Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. ( Baughman, RP; Lower, EE; Malhotra, A; Surdulescu, V, 2013) |
| "Examine the efficacy of armodafinil in improving cognition in patients with multiple sclerosis (MS)." | 9.16 | Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study. ( Brown, A; Bruce, J; Hancock, L; Henkelman, E; Lynch, S; Roberg, B, 2012) |
| "To reassess the effect of modafinil, a wakefulness-promoting artificial psychostimulant, on fatigue and neuropsychological measures in patients with multiple sclerosis." | 9.15 | HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. ( Broemel, F; Daumer, M; Heesen, C; Möller, F; Neuhaus, A; Poettgen, J, 2011) |
| "Our objective was to determine whether modafinil alleviates fatigue in patients with amyotrophic lateral sclerosis (ALS)." | 9.14 | Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. ( Chew, S; Gordon, PH; McElhiney, M; Mitsumoto, H; Rabkin, JG; Rabkin, R, 2009) |
| "The authors found that modafinil improved cognitive performance in breast cancer survivors by enhancing some memory and attention skills." | 9.14 | The effect of modafinil on cognitive function in breast cancer survivors. ( Adams, MJ; Fisher, SG; Kohli, S; Mapstone, ME; Morrow, GR; Roscoe, JA; Tra, Y; Wesnes, KA, 2009) |
| "To investigate the effects of Modafinil on focused attention, motor function and motor excitability in patients with multiple sclerosis (MS) and fatigue." | 9.14 | Modafinil effects in multiple sclerosis patients with fatigue. ( Heesen, C; Lange, R; Liepert, J; Volkmer, M, 2009) |
| "To evaluate the efficacy, tolerability, and safety of modafinil for negative symptoms, cognition, and wakefulness/fatigue in DSM-IV-diagnosed schizophrenia patients treated with clozapine." | 9.14 | Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. ( Cather, C; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Macklin, EA; Walsh, JP, 2009) |
| "To evaluate the efficacy and safety of modafinil in the treatment of fatigue in patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and to assess effect on depressive symptoms." | 9.14 | Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. ( McElhiney, MC; McGrath, PJ; Rabkin, JG; Rabkin, R, 2010) |
| "The authors conducted a multicenter, randomized, double-blind, placebo-controlled, phase 3, clinical trial to examine the effect of modafinil on patient-reported fatigue in cancer patients undergoing chemotherapy." | 9.14 | A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas ( Esparaz, BT; Heckler, C; Hemstad, A; Hopkins, JO; Janelsins, M; Jean-Pierre, P; Mohile, S; Morrow, GR; Peppone, L; Roscoe, JA, 2010) |
| "This study indicates that modafinil is effective and well tolerated in the treatment of posttraumatic EDS but not of fatigue." | 9.14 | Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. ( Bassetti, CL; Baumann, CR; Kaiser, PR; Meier, J; Stocker, R; Thomann, J; Valko, PO; Werth, E, 2010) |
| "The purpose of this study was to test whether modafinil is effective in alleviating the symptoms of fatigue in postpolio patients, because it has been helpful for such symptoms in other neurologic disorders." | 9.12 | Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients. ( Allidina, A; Chan, KM; Rydz, D; Shuaib, A; Strohschein, FJ; Westbury, CF, 2006) |
| "Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood." | 9.12 | Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. ( Arora, S; DeBattista, C; Fava, M; Hughes, RJ; Thase, ME, 2006) |
| "To explore, in an open label study, the responses of PBC patients suffering from significant daytime somnolence and associated fatigue to modafinil therapy." | 9.12 | An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. ( Jones, DE; Newton, JL, 2007) |
| "To determine if modafinil can improve fatigue in patients with post-polio syndrome." | 9.12 | Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. ( Campbell, WW; Dalakas, MC; Halstead, LS; Jabbari, B; Kelley, KF; Livornese, K; Olsen, CH; Prokhorenko, OA; Salajegheh, MK; Vasconcelos, OM; Vo, AH, 2007) |
| "Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue." | 9.12 | Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007) |
| "To determine whether treatment with modafinil for excessive sleepiness improves fatigue, mood, and health-related quality of life (HRQOL) in patients with narcolepsy." | 9.11 | Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. ( Becker, PM; Feldman, NT; Hughes, RJ; Schwartz, JR, 2004) |
| " This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue." | 9.11 | Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004) |
| "This pilot study shows encouraging results for modafinil in alleviation of fatigue in HIV+ patients." | 9.11 | Modafinil treatment for fatigue in HIV+ patients: a pilot study. ( Ferrando, SJ; McElhiney, MC; Rabkin, JG; Rabkin, R, 2004) |
| " This multicenter, placebo-controlled study evaluated the efficacy of modafinil augmentation in major depressive disorder (MDD) patients with fatigue and excessive sleepiness despite selective serotonin reuptake inhibitor (SSRI) monotherapy." | 9.11 | A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. ( DeBattista, C; Fava, M; Thase, ME, 2005) |
| "To assess whether modafinil, a wakefulness-promoting agent, is useful for fatigue in patients with multiple sclerosis (MS)." | 9.11 | Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. ( Clanet, M; Confavreux, C; Debouverie, M; Edan, G; Lubetzki, C; Moreau, T; Pelletier, J; Rumbach, L; Stankoff, B; Waubant, E, 2005) |
| "To assess the effects of modafinil on fatigue, symptoms, attention, working memory, and executive functioning in schizophrenia patients treated with psychotropic medications." | 9.11 | Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. ( Alvir, J; Gunduz-Bruce, H; Meyer, S; Rosenthal, MH; Schooler, NR; Sevy, S; Visweswaraiah, H, 2005) |
| "Modafinil may be a useful adjunct therapy for the short-term management of residual fatigue and sleepiness in patients who are partial responders to antidepressant therapy." | 9.10 | Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. ( DeBattista, C; Doghramji, K; Fieve, RR; Menza, MA; Rosenthal, MH, 2003) |
| "To assess the efficacy and safety of modafinil for the treatment of fatigue in multiple sclerosis (MS)." | 9.10 | Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. ( Blumenfeld, AM; Lynn, DJ; Nagaraja, HN; Pollak, CP; Rammohan, KW; Rosenberg, JH, 2002) |
| "We performed a systematic review in accordance with the Cochrane Handbook for Systematic Reviews of Interventions recommendations to assess the efficacy and safety of modafinil in poststroke patients." | 9.01 | Modafinil for poststroke patients: A systematic review. ( Cabrera Martimbianco, AL; da Silva, LDGM; Fernandes, CAA; Ferreira, DBGM; Hosni, ND; Latorraca, COC; Pacheco, RL; Riera, R; Vianna Pachito, D, 2019) |
| "Clinical trials examining the therapeutic benefit of modafinil in MS fatigue provide conflicting data." | 8.98 | Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. ( Jie, C; Kuiqing, L; Shangyan, H; Weixiong, L; Yumin, X, 2018) |
| "We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of modafinil or armodafinil (ar/mod) augmentation in schizophrenia." | 8.91 | Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. ( Andrade, C; Kisely, S; Monteiro, I; Rao, S, 2015) |
| "Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder and obstructive sleep apnea." | 8.89 | Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. ( Dong, Y; Han, X; Hou, L; Huang, C; Sheng, P; Wang, X; Yu, M, 2013) |
| "To review the efficacy and safety of off-label use of modafinil in the treatment of multiple sclerosis (MS)-related fatigue." | 8.86 | Modafinil for the treatment of multiple sclerosis-related fatigue. ( Brown, JN; Howard, CA; Kemp, DW, 2010) |
| "Given recent reports about the off-label use of modafinil as an adjuvant for the treatment of antipsychotic-associated sedation in schizophrenia patients and the recent interest in its putative cognitive-enhancing effects in this population, we present a systematic review of available data on trials of modafinil as an adjuvant in the treatment of cognitive deficits, negative symptoms, and antipsychotic-induced fatigue, and its tolerability." | 8.85 | Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. ( Anbarasan, D; Lindenmayer, JP; Saavedra-Velez, C; Yusim, A, 2009) |
| "To review the efficacy and safety of modafinil in the treatment of cancer-related fatigue (CRF)." | 8.85 | Efficacy and safety of modafinil in the treatment of cancer-related fatigue. ( Bird, HM; Cooper, MR; Steinberg, M, 2009) |
| "To evaluate the literature discussing the use of modafinil in the treatment of residual symptoms of fatigue in patients with depression." | 8.84 | Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. ( Cates, ME; Freeman, MK; Lam, JY, 2007) |
| "Modafinil use in acute in-hospital stroke patients with moderate stroke complicated by lethargy and fatigue was associated with improved discharge disposition." | 7.96 | Modafinil in Recovery after Stroke (MIRAS): A Retrospective Study. ( Cross, DB; Czeisler, B; Golub, D; Hernandez, C; Ishida, K; Karoub, A; Lord, A; Medicherla, C; Tiu, J; Torres, J; Wu, C; Yaghi, S, 2020) |
| "This study explored the cost-effectiveness of modafinil in treating post-stroke fatigue in the Australian context, by determining its incremental cost-effectiveness ratio (ICER) and by simulating the potential cost-savings on a national scale, through a re-analysis of MIDAS trial data." | 7.96 | Exploring the Economic Benefits of Modafinil for Post-Stroke Fatigue in Australia: A Cost-Effectiveness Evaluation. ( Bajorek, B; Bivard, A; Gao, L; Garcia-Esperon, C; Holliday, E; Levi, C; Lillicrap, T; Parsons, M; Spratt, N, 2020) |
| "Modafinil is sometimes used in the clinical setting for treating multiple sclerosis (MS) fatigue, despite conflicting and disappointing results from clinical trials." | 7.76 | Modafinil for multiple sclerosis fatigue: does it work? ( Hobart, JC; Littleton, ET; Palace, J, 2010) |
| "the authors conducted an open-label investigation examining the effects of modafinil in reducing fatigue in patients with cancer, undergoing cancer treatment, and receiving opioid therapy." | 7.76 | [Modafinil for the treatment of cancer-related fatigue : an intervention study]. ( Junker, U; Kühn, KU; Nadstawek, J; Vater, S; Wartenberg, HC; Wirz, S, 2010) |
| "Modafinil may be a potentially effective treatment for primary biliary cirrhosis (PBC)-related fatigue." | 7.75 | Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. ( de Jongh, M; Ian Gan, S; Kaplan, MM, 2009) |
| "Modafinil has anecdotal response to neurological fatigue, but such an effect may depend on the type and location of cerebral impairment." | 7.75 | Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients. ( Annoni, JM; Bassetti, C; Brioschi, A; Gramigna, S; Ruffieux, C; Schluep, M; Staub, F; Werth, E, 2009) |
| "To evaluate the value of visual and auditory P300 for predicting the response of multiple sclerosis-related fatigue to modafinil treatment, 33 patients were treated with 100 mg modafinil once daily for 4 weeks, following a 4-week baseline phase and an optional 8-week extension phase." | 7.74 | P300 and treatment effect of modafinil on fatigue in multiple sclerosis. ( D'hooghe, MB; De Deyn, PP; Despontin, M; Kos, D; Nagels, G; Vleugels, L, 2007) |
| "To investigate the effects of modafinil, a new central stimulant, on visual and auditory motion reaction ability and subjective fatigue level during 48 h sleep deprivation (SD)." | 7.72 | [Effects of modafinil on visual and auditory reaction abilities and subjective fatigue level during 48 h sleep deprivation]. ( Li, T; Li, YF; Tang, GX; Wei, SH; Xin, YM; Zhan, H, 2003) |
| "The extent to which modafinil and caffeine reverse fatigue effects (defined as performance decrements with time on task) during total sleep deprivation was investigated." | 7.72 | Modafinil vs. caffeine: effects on fatigue during sleep deprivation. ( Balkin, TJ; Belenky, G; Kautz, MA; Thorne, DR; Wesensten, NJ, 2004) |
| "Three patients discontinued modafinil because of AEs (nervousness, dizziness)." | 7.71 | Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. ( Maida, EM; Rupp, M; Schwarz, S; Zifko, UA; Zipko, HT, 2002) |
| "Post-stroke fatigue has a significant impact on stroke survivors' mental and physical well-being." | 6.90 | Modafinil treatment modulates functional connectivity in stroke survivors with severe fatigue. ( Bivard, A; Goodin, P; Levi, CR; Lillicrap, T; Parsons, MW; Spratt, NJ; Visser, MM, 2019) |
| "Fatigue is a common and distressing symptom of MS which is unrelated to its clinical form, stage of development, the degree of disability, or the lesion load on magnetic resonance imaging." | 6.78 | Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil. ( Bibani, RH; Bradshaw, CM; Constantinescu, CS; Langley, RW; Niepel, G; Szabadi, E; Vilisaar, J, 2013) |
| "Fatigue is prevalent among patients with hepatitis C virus (HCV) and with HIV/AIDS but there are no established fatigue treatments for either condition or their combination." | 6.76 | Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C. ( McElhiney, MC; Rabkin, JG; Rabkin, R, 2011) |
| "Modafinil is a stimulant with a selective site of action in the brain that is better tolerated than traditional stimulants, such as methylphenidate." | 6.74 | Modafinil for the treatment of fatigue in lung cancer: a pilot study. ( Booden, D; Dhillan, R; Fife, K; Forbes, K; Spathis, A; Vrotsou, K, 2009) |
| "Fatigue is a frequently reported and disabling symptom in patients with systemic lupus erythematosus (SLE)." | 5.62 | Improvement of lupus-associated fatigue with modafinil: Report of two cases. ( Korsten, P; Piantoni, S, 2021) |
| "To determine whether armodafinil reduces fatigue in patients with HGG and moderate-to-severe fatigue." | 5.51 | Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial. ( Brown, PD; Cerhan, JL; Jaeckle, KA; Kizilbash, SH; Kohli, S; Le-Rademacher, J; Liu, H; Loprinzi, CL; McMurray, RP; Mehta, MP; Porter, AB; Sloan, J; Villano, JL, 2022) |
| " Methylphenidate had positive effects on self-reported fatigue as well as on declarative memory 24 hours after learning; caffeine had a positive effect on sustained attention; there was no significant effect of modafinil in any of the instruments of our test battery." | 5.41 | Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine. ( Bovy, L; Dresler, M; Kühn, S; Ohla, K; Repantis, D, 2021) |
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 5.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "The aim of this study was to compare the efficacy and safety of modafinil and dexamethasone in the management of cancer-related fatigue and their effects on quality of life (QoL)." | 5.41 | Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Deb, U; Mukhopadhyay, S, 2021) |
| "IFN-alpha-induced depression is presumed to be composed of two overlapping syndromes: a depression-specific syndrome characterized by depressed mood, anxiety, and cognitive complaints, and a neurovegetative syndrome consisting of fatigue, anorexia, somatic pain complaints, and psychomotor retardation [1]." | 5.34 | Modafinil's use in combating interferon-induced fatigue. ( Balan, V; Krahn, LE; Martin, KA; Rosati, MJ, 2007) |
| "Modafinil is a wakefulness-promoting agent that the FDA has approved for the treatment of excessive daytime sleepiness associated with narcolepsy." | 5.32 | Modafinil for the treatment of pain-associated fatigue: review and case report. ( Cole, B; Cutler, RB; Fishbain, DA; Lewis, J; Rosomoff, HL; Steele-Rosomoff, R, 2004) |
| "Fatigue is one of the most frequent and disabling symptoms in multiple sclerosis (MS) patients." | 5.32 | [Modafinil and fatigue in multiple sclerosis]. ( Montalbán, X; Téllez, N, 2004) |
| " Eligible participants with MS and significant fatigue severity are randomly assigned (1:1:1) to received either CBT, modafinil, or a combination of CBT and modafinil for 12 weeks." | 5.30 | A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the "COMBO-MS" trial. ( Alschuler, KN; Braley, TJ; Ehde, DM; Kratz, AL; Kulkarni, S; Little, R; Pickup, K; von Geldern, G, 2019) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 5.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "This pilot study, the first double-blind, placebo-controlled trial assessing whether a wake-promoting therapy can improve residual daytime sleepiness in patients with treated nocturia, indicates the promise of armodafinil for addressing this residual sleepiness and provides impetus to carry out a large-scale study to definitively evaluate whether armodafinil is an effective therapy for the many patients with nocturia who experience daytime sleepiness that persists, despite their receiving standard therapy for this condition." | 5.24 | Double-Blind, Placebo-Controlled, Crossover Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia. ( Krystal, AD; Preud'homme, XA, 2017) |
| "This study aimed to assess the efficacy of modafinil, a wakefulness-promoting agent in alleviating post-stroke fatigue ≥3 months after stroke." | 5.24 | MIDAS (Modafinil in Debilitating Fatigue After Stroke): A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial. ( Attia, J; Bivard, A; Holliday, E; Krishnamurthy, V; Levi, CR; Lillicrap, T; Nilsson, M; Pagram, H; Parsons, M, 2017) |
| "This secondary analysis was performed using the MOTIF database, from a phase III, randomised, double-blind, placebo-controlled study of modafinil (200 mg/day for 15 days) for docetaxel-related fatigue in men with metastatic prostate cancer [1]." | 5.24 | Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis. ( Bergin, ART; de Souza, P; Hovey, E; Lloyd, A; Marx, G; Parente, P; Rapke, T, 2017) |
| " Studies in early radiotherapy treatment phase (five studies) Pharmacological studies in the "early radiotherapy treatment phase" were designed to prevent or ameliorate cognitive deficits and included drugs used in dementia (memantine) and fatigue (d-threo-methylphenidate hydrochloride)." | 5.22 | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. ( Brown, PD; Day, J; Gehring, K; Grosshans, D; Kirkman, MA; Li, J; Taphoorn, M; Zienius, K, 2022) |
| "This study aims to obtain preliminary data on the efficacy of armodafinil for improving menopause-related fatigue and quality of life." | 5.22 | Armodafinil for fatigue associated with menopause: an open-label trial. ( Barsky, M; Cohen, L; Freeman, MP; Galvan, T; Joffe, H; Kim, S; Meyer, F; Petrillo, L, 2016) |
| "To evaluate the impact of modafinil on "free" and "cued" recall of clinical information in fatigued but nonsleep-deprived clinicians." | 5.22 | Structured cues or modafinil for fatigue amelioration in clinicians? A double-blind, randomized controlled trial of critical clinical information recall in fatigued clinicians. ( Darzi, A; Flindall, I; Goodship, J; Leff, DR; Sugden, C, 2016) |
| "CBT-I with and without armodafinil resulted in a clinically and statistically significant reduction of subjective daytime fatigue in cancer survivors with chronic insomnia." | 5.22 | Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Hoefler, J; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Shayne, M, 2016) |
| "To assess the efficacy of modafinil for the treatment of new learning and memory deficits and fatigue in multiple sclerosis." | 5.22 | Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial. ( Chiaravalloti, ND; DeLuca, J; Elovic, E; Ford-Johnson, L; Lengenfelder, J; Zhang, J, 2016) |
| "The aim of this study was to examine the effect of modafinil on depression via a secondary data analysis of a randomized clinical trial of modafinil for fatigue in cancer patients." | 5.22 | Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy. ( Conley, CC; Dakhil, S; Gross, H; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Scalzo, AJ, 2016) |
| "While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study." | 5.22 | A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. ( Alexander, BM; Arvold, ND; Doherty, L; Drappatz, J; Fadul, CE; Gaffey, SC; Hammond, S; Kesari, S; LaFrankie, D; Lee, EQ; Muzikansky, A; Nayak, L; Norden, AD; Pulverenti, J; Reardon, DA; Rinne, ML; Ruland, SF; Smith, KH; Stefanik, J; Wen, PY; Wong, ET, 2016) |
| "MIDAS is a phase II, single-centre, prospective, double-blinded, randomised, crossover trial of modafinil for the treatment of persistent fatigue in survivors of ischaemic stroke." | 5.22 | Modafinil In Debilitating fatigue After Stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial. ( Attia, J; Bivard, A; Krishnamurthy, V; Levi, CR; Lillicrap, T; Nilsson, M; Parsons, MW, 2016) |
| "This double-blind, placebo-controlled phase 3 trial evaluated the efficacy of armodafinil in MM patients with evidence of moderate fatigue." | 5.20 | A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. ( Andreu-Vieyra, C; Berenson, JR; Charu, V; Chen, CS; Nassir, Y; Sanani, S; Schlutz, M; Shamasunder, HK; Swift, RA; Vescio, R; Woliver, TB; Yellin, O, 2015) |
| "A phase II, multi-institutional, placebo-controlled randomized trial assessed feasibility of armodafinil 150 mg/day in participants receiving brain RT, from whom we obtained estimates of variability for fatigue, sleepiness, QOL, cognitive function, and treatment effect." | 5.20 | Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. ( Bryant, D; Case, D; Chan, MD; Grisell, D; Lesser, GJ; Lu, L; Monitto, DC; Naughton, MJ; Page, BR; Rapp, SR; Savona, SR; Shah, S; Shaw, EG, 2015) |
| "One thousand one hundred twenty-one patients with stroke were screened and 41 patients included, 21 received modafinil." | 5.20 | Modafinil May Alleviate Poststroke Fatigue: A Randomized, Placebo-Controlled, Double-Blinded Trial. ( Damgaard, B; Overgaard, K; Poulsen, MB; Rasmussen, RS; Zerahn, B, 2015) |
| "This multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy of modafinil in patients with metastatic prostate or breast cancer undergoing docetaxel chemotherapy (every 21 days; minimum dose 50 mg/m(2))." | 5.19 | Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. ( Abdi, E; Bonaventura, A; Craft, P; de Souza, P; Hill, A; Hovey, E; Lloyd, A; Marx, G; Michele, A; Parente, P; Rapke, T, 2014) |
| "Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting." | 5.19 | Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. ( Bahadori, R; Bates, N; Benepal, T; Blackhall, F; Dutton, S; Fife, K; O'Brien, M; Spathis, A; Stone, P; Wee, B; Wharton, R, 2014) |
| " Relative to baseline, patients reported lower fatigue severity (CIS) and better motivation (CIS) in both the modafinil (P = ." | 5.17 | The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. ( Boele, FW; Cleijne, W; de Groot, M; Douw, L; Heimans, JJ; Klein, M; Reijneveld, JC; Taphoorn, MJ; van Thuijl, HF, 2013) |
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 5.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "This was a double-blind, placebo-controlled, crossover study of sarcoidosis patients followed up in one sarcoidosis clinic Sarcoidosis patients with fatigue received either armodafinil or placebo with eight weeks of therapy for each arm and a two week washout period before crossover to the other treatment." | 5.17 | Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. ( Baughman, RP; Lower, EE; Malhotra, A; Surdulescu, V, 2013) |
| "Examine the efficacy of armodafinil in improving cognition in patients with multiple sclerosis (MS)." | 5.16 | Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study. ( Brown, A; Bruce, J; Hancock, L; Henkelman, E; Lynch, S; Roberg, B, 2012) |
| "To reassess the effect of modafinil, a wakefulness-promoting artificial psychostimulant, on fatigue and neuropsychological measures in patients with multiple sclerosis." | 5.15 | HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. ( Broemel, F; Daumer, M; Heesen, C; Möller, F; Neuhaus, A; Poettgen, J, 2011) |
| "These results justify additional investigation into the efficacy of armodafinil to promote sustained vigilance in military operational settings where fatigue-related performance decrements are especially problematic." | 5.15 | A single dose of armodafinil significantly promotes vigilance 11 hours post-dose. ( Arnold, RD; Phillips, JB; Simmons, RG, 2011) |
| "Our objective was to determine whether modafinil alleviates fatigue in patients with amyotrophic lateral sclerosis (ALS)." | 5.14 | Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. ( Chew, S; Gordon, PH; McElhiney, M; Mitsumoto, H; Rabkin, JG; Rabkin, R, 2009) |
| "The authors found that modafinil improved cognitive performance in breast cancer survivors by enhancing some memory and attention skills." | 5.14 | The effect of modafinil on cognitive function in breast cancer survivors. ( Adams, MJ; Fisher, SG; Kohli, S; Mapstone, ME; Morrow, GR; Roscoe, JA; Tra, Y; Wesnes, KA, 2009) |
| "To investigate the effects of Modafinil on focused attention, motor function and motor excitability in patients with multiple sclerosis (MS) and fatigue." | 5.14 | Modafinil effects in multiple sclerosis patients with fatigue. ( Heesen, C; Lange, R; Liepert, J; Volkmer, M, 2009) |
| "The primary objective of this open-label pilot study was to evaluate the safety, and efficacy of modafinil in improving cancer-related fatigue (CRF) as measured by the Brief Fatigue Inventory (BFI)." | 5.14 | A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. ( Baum, L; Blackhall, L; Farace, E; Petroni, G; Shu, J, 2009) |
| "To evaluate the efficacy, tolerability, and safety of modafinil for negative symptoms, cognition, and wakefulness/fatigue in DSM-IV-diagnosed schizophrenia patients treated with clozapine." | 5.14 | Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. ( Cather, C; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Macklin, EA; Walsh, JP, 2009) |
| "To evaluate the efficacy and safety of modafinil in the treatment of fatigue in patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and to assess effect on depressive symptoms." | 5.14 | Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. ( McElhiney, MC; McGrath, PJ; Rabkin, JG; Rabkin, R, 2010) |
| "The authors conducted a multicenter, randomized, double-blind, placebo-controlled, phase 3, clinical trial to examine the effect of modafinil on patient-reported fatigue in cancer patients undergoing chemotherapy." | 5.14 | A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas ( Esparaz, BT; Heckler, C; Hemstad, A; Hopkins, JO; Janelsins, M; Jean-Pierre, P; Mohile, S; Morrow, GR; Peppone, L; Roscoe, JA, 2010) |
| "This study indicates that modafinil is effective and well tolerated in the treatment of posttraumatic EDS but not of fatigue." | 5.14 | Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. ( Bassetti, CL; Baumann, CR; Kaiser, PR; Meier, J; Stocker, R; Thomann, J; Valko, PO; Werth, E, 2010) |
| "The purpose of this study was to test whether modafinil is effective in alleviating the symptoms of fatigue in postpolio patients, because it has been helpful for such symptoms in other neurologic disorders." | 5.12 | Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients. ( Allidina, A; Chan, KM; Rydz, D; Shuaib, A; Strohschein, FJ; Westbury, CF, 2006) |
| "Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood." | 5.12 | Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. ( Arora, S; DeBattista, C; Fava, M; Hughes, RJ; Thase, ME, 2006) |
| "To explore, in an open label study, the responses of PBC patients suffering from significant daytime somnolence and associated fatigue to modafinil therapy." | 5.12 | An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. ( Jones, DE; Newton, JL, 2007) |
| "To determine if modafinil can improve fatigue in patients with post-polio syndrome." | 5.12 | Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. ( Campbell, WW; Dalakas, MC; Halstead, LS; Jabbari, B; Kelley, KF; Livornese, K; Olsen, CH; Prokhorenko, OA; Salajegheh, MK; Vasconcelos, OM; Vo, AH, 2007) |
| "Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue." | 5.12 | Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007) |
| "To determine whether treatment with modafinil for excessive sleepiness improves fatigue, mood, and health-related quality of life (HRQOL) in patients with narcolepsy." | 5.11 | Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. ( Becker, PM; Feldman, NT; Hughes, RJ; Schwartz, JR, 2004) |
| "Modafinil significantly reduces fatigue and improves feelings of alertness and energy in postoperative patients." | 5.11 | Modafinil improves recovery after general anesthesia. ( Dunn, JB; Goldberg, ME; Hojat, M; Khaleghi, B; Larijani, GE; Marr, AT, 2004) |
| " This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue." | 5.11 | Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004) |
| "The stimulant modafinil has proved to be an effective treatment modality for narcolepsy and related sleep disorders and is also being studied for use during sustained military operations to ameliorate the effects of fatigue due to sleep loss." | 5.11 | Effects of modafinil on cognitive and meta-cognitive performance. ( Baranski, JV; Dinich, P; Jacobs, I; Pigeau, R, 2004) |
| "In patients with MDD who experience sedation as a side effect of antidepressant therapy, adjunctive modafinil improved wakefulness and reduced fatigue." | 5.11 | An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. ( Azhar, N; Cole, K; Hopkins, G; Husain, J; Jones, N; Nihalani, N; Schwartz, TL; Simionescu, M, 2004) |
| "This pilot study shows encouraging results for modafinil in alleviation of fatigue in HIV+ patients." | 5.11 | Modafinil treatment for fatigue in HIV+ patients: a pilot study. ( Ferrando, SJ; McElhiney, MC; Rabkin, JG; Rabkin, R, 2004) |
| " This multicenter, placebo-controlled study evaluated the efficacy of modafinil augmentation in major depressive disorder (MDD) patients with fatigue and excessive sleepiness despite selective serotonin reuptake inhibitor (SSRI) monotherapy." | 5.11 | A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. ( DeBattista, C; Fava, M; Thase, ME, 2005) |
| "To assess whether modafinil, a wakefulness-promoting agent, is useful for fatigue in patients with multiple sclerosis (MS)." | 5.11 | Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. ( Clanet, M; Confavreux, C; Debouverie, M; Edan, G; Lubetzki, C; Moreau, T; Pelletier, J; Rumbach, L; Stankoff, B; Waubant, E, 2005) |
| "To assess the effects of modafinil on fatigue, symptoms, attention, working memory, and executive functioning in schizophrenia patients treated with psychotropic medications." | 5.11 | Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. ( Alvir, J; Gunduz-Bruce, H; Meyer, S; Rosenthal, MH; Schooler, NR; Sevy, S; Visweswaraiah, H, 2005) |
| "Modafinil may be a useful adjunct therapy for the short-term management of residual fatigue and sleepiness in patients who are partial responders to antidepressant therapy." | 5.10 | Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. ( DeBattista, C; Doghramji, K; Fieve, RR; Menza, MA; Rosenthal, MH, 2003) |
| "To assess the efficacy and safety of modafinil for the treatment of fatigue in multiple sclerosis (MS)." | 5.10 | Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. ( Blumenfeld, AM; Lynn, DJ; Nagaraja, HN; Pollak, CP; Rammohan, KW; Rosenberg, JH, 2002) |
| "We performed a systematic review in accordance with the Cochrane Handbook for Systematic Reviews of Interventions recommendations to assess the efficacy and safety of modafinil in poststroke patients." | 5.01 | Modafinil for poststroke patients: A systematic review. ( Cabrera Martimbianco, AL; da Silva, LDGM; Fernandes, CAA; Ferreira, DBGM; Hosni, ND; Latorraca, COC; Pacheco, RL; Riera, R; Vianna Pachito, D, 2019) |
| "Clinical trials examining the therapeutic benefit of modafinil in MS fatigue provide conflicting data." | 4.98 | Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. ( Jie, C; Kuiqing, L; Shangyan, H; Weixiong, L; Yumin, X, 2018) |
| "We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of modafinil or armodafinil (ar/mod) augmentation in schizophrenia." | 4.91 | Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. ( Andrade, C; Kisely, S; Monteiro, I; Rao, S, 2015) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| "Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder and obstructive sleep apnea." | 4.89 | Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. ( Dong, Y; Han, X; Hou, L; Huang, C; Sheng, P; Wang, X; Yu, M, 2013) |
| "Although most research to date has focused on the use of methylphenidate for the relief of symptoms such as asthenia and depression in cancer patients, there is growing interest in the use of modafinil, a psychostimulant with a structure and mechanism that differs from other drugs belonging to this group." | 4.87 | The use of psychostimulants in cancer patients. ( Centeno, C; Portela, MA; Rubiales, AS, 2011) |
| "To review the efficacy and safety of off-label use of modafinil in the treatment of multiple sclerosis (MS)-related fatigue." | 4.86 | Modafinil for the treatment of multiple sclerosis-related fatigue. ( Brown, JN; Howard, CA; Kemp, DW, 2010) |
| " Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis." | 4.86 | Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010) |
| "Given recent reports about the off-label use of modafinil as an adjuvant for the treatment of antipsychotic-associated sedation in schizophrenia patients and the recent interest in its putative cognitive-enhancing effects in this population, we present a systematic review of available data on trials of modafinil as an adjuvant in the treatment of cognitive deficits, negative symptoms, and antipsychotic-induced fatigue, and its tolerability." | 4.85 | Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. ( Anbarasan, D; Lindenmayer, JP; Saavedra-Velez, C; Yusim, A, 2009) |
| "To review the efficacy and safety of modafinil in the treatment of cancer-related fatigue (CRF)." | 4.85 | Efficacy and safety of modafinil in the treatment of cancer-related fatigue. ( Bird, HM; Cooper, MR; Steinberg, M, 2009) |
| "To evaluate the literature discussing the use of modafinil in the treatment of residual symptoms of fatigue in patients with depression." | 4.84 | Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. ( Cates, ME; Freeman, MK; Lam, JY, 2007) |
| "Modafinil use in acute in-hospital stroke patients with moderate stroke complicated by lethargy and fatigue was associated with improved discharge disposition." | 3.96 | Modafinil in Recovery after Stroke (MIRAS): A Retrospective Study. ( Cross, DB; Czeisler, B; Golub, D; Hernandez, C; Ishida, K; Karoub, A; Lord, A; Medicherla, C; Tiu, J; Torres, J; Wu, C; Yaghi, S, 2020) |
| "This study explored the cost-effectiveness of modafinil in treating post-stroke fatigue in the Australian context, by determining its incremental cost-effectiveness ratio (ICER) and by simulating the potential cost-savings on a national scale, through a re-analysis of MIDAS trial data." | 3.96 | Exploring the Economic Benefits of Modafinil for Post-Stroke Fatigue in Australia: A Cost-Effectiveness Evaluation. ( Bajorek, B; Bivard, A; Gao, L; Garcia-Esperon, C; Holliday, E; Levi, C; Lillicrap, T; Parsons, M; Spratt, N, 2020) |
| "HIV+ participants with fatigue were treated with armodafinil." | 3.91 | Returning to work after fatigue treatment and counseling in HIV/AIDS. ( Daughters, SB; McElhiney, MC; Rabkin, JG; Timperlake, EC; Wainberg, ML, 2019) |
| "There were 1948 treatment histories for modafinil and 1394 treatment reports for amitriptyline reported across five PatientsLikeMe communities (multiple sclerosis, Parkinson's disease, mood conditions, fibromyalgia/chronic fatigue syndrome, and amyotrophic lateral sclerosis)." | 3.77 | Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe. ( Frost, J; Heywood, J; Okun, S; Vaughan, T; Wicks, P, 2011) |
| "Modafinil is sometimes used in the clinical setting for treating multiple sclerosis (MS) fatigue, despite conflicting and disappointing results from clinical trials." | 3.76 | Modafinil for multiple sclerosis fatigue: does it work? ( Hobart, JC; Littleton, ET; Palace, J, 2010) |
| "the authors conducted an open-label investigation examining the effects of modafinil in reducing fatigue in patients with cancer, undergoing cancer treatment, and receiving opioid therapy." | 3.76 | [Modafinil for the treatment of cancer-related fatigue : an intervention study]. ( Junker, U; Kühn, KU; Nadstawek, J; Vater, S; Wartenberg, HC; Wirz, S, 2010) |
| "Modafinil may be a potentially effective treatment for primary biliary cirrhosis (PBC)-related fatigue." | 3.75 | Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. ( de Jongh, M; Ian Gan, S; Kaplan, MM, 2009) |
| "Modafinil has anecdotal response to neurological fatigue, but such an effect may depend on the type and location of cerebral impairment." | 3.75 | Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients. ( Annoni, JM; Bassetti, C; Brioschi, A; Gramigna, S; Ruffieux, C; Schluep, M; Staub, F; Werth, E, 2009) |
| "To evaluate the value of visual and auditory P300 for predicting the response of multiple sclerosis-related fatigue to modafinil treatment, 33 patients were treated with 100 mg modafinil once daily for 4 weeks, following a 4-week baseline phase and an optional 8-week extension phase." | 3.74 | P300 and treatment effect of modafinil on fatigue in multiple sclerosis. ( D'hooghe, MB; De Deyn, PP; Despontin, M; Kos, D; Nagels, G; Vleugels, L, 2007) |
| "Caffeine and modafinil are psychostimulants that may be taken by fighter aircraft pilots to reduce fatigue." | 3.73 | Psychostimulants and G tolerance in rhesus monkeys: effects of oral modafinil and injected caffeine. ( Bonneau, D; Drogou, C; Etienne, X; Florence, G; Gomez-Merino, D; Huart, B; Pradeau, P; Riondet, L; Serra, A; van Beers, P, 2005) |
| "Adult affective disorder patients, whether unipolar or bipolar, can use modafinil to relieve symptoms of depression, including fatigue and sleepiness, without risking a switch in their mood or developing tolerance or abuse of this medication." | 3.73 | Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. ( Nasr, S; Steiner, K; Wendt, B, 2006) |
| "To investigate the effects of modafinil, a new central stimulant, on visual and auditory motion reaction ability and subjective fatigue level during 48 h sleep deprivation (SD)." | 3.72 | [Effects of modafinil on visual and auditory reaction abilities and subjective fatigue level during 48 h sleep deprivation]. ( Li, T; Li, YF; Tang, GX; Wei, SH; Xin, YM; Zhan, H, 2003) |
| "The extent to which modafinil and caffeine reverse fatigue effects (defined as performance decrements with time on task) during total sleep deprivation was investigated." | 3.72 | Modafinil vs. caffeine: effects on fatigue during sleep deprivation. ( Balkin, TJ; Belenky, G; Kautz, MA; Thorne, DR; Wesensten, NJ, 2004) |
| "The purpose of this study was to determine whether modafinil (100 mg after 17, 22, and 27 h without sleep) would attenuate the effects of fatigue on fighter-pilot mood and performance during 37 h of continuous wakefulness." | 3.72 | Modafinil's effects on simulator performance and mood in pilots during 37 h without sleep. ( Brown, DL; Caldwell, JA; Caldwell, JL; Smith, JK, 2004) |
| "Three patients discontinued modafinil because of AEs (nervousness, dizziness)." | 3.71 | Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. ( Maida, EM; Rupp, M; Schwarz, S; Zifko, UA; Zipko, HT, 2002) |
| "Methylphenidate and modafinil were equivalent to one another." | 3.01 | Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis. ( Boldt, G; Bruera, E; Chiu, L; Chow, R; Lock, M; Prsic, E; Sanatani, M, 2023) |
| "Post-stroke fatigue has a significant impact on stroke survivors' mental and physical well-being." | 2.90 | Modafinil treatment modulates functional connectivity in stroke survivors with severe fatigue. ( Bivard, A; Goodin, P; Levi, CR; Lillicrap, T; Parsons, MW; Spratt, NJ; Visser, MM, 2019) |
| "Fatigue is a common and disabling symptom in people with a primary brain tumour (PBT)." | 2.82 | Interventions for the management of fatigue in adults with a primary brain tumour. ( Bulbeck, H; Cachia, D; Day, J; Rooney, AG; Tremont Lukats, IW; Wefel, J; Yust-Katz, S, 2022) |
| "Fatigue is a common and distressing symptom of MS which is unrelated to its clinical form, stage of development, the degree of disability, or the lesion load on magnetic resonance imaging." | 2.78 | Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil. ( Bibani, RH; Bradshaw, CM; Constantinescu, CS; Langley, RW; Niepel, G; Szabadi, E; Vilisaar, J, 2013) |
| "Fatigue is prevalent among patients with hepatitis C virus (HCV) and with HIV/AIDS but there are no established fatigue treatments for either condition or their combination." | 2.76 | Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C. ( McElhiney, MC; Rabkin, JG; Rabkin, R, 2011) |
| "Modafinil 200 mg was administered to the treatment group patients 1 h before sedation/analgesia." | 2.75 | Modafinil reduces patient-reported tiredness after sedation/analgesia but does not improve patient psychomotor skills. ( Boesjes, H; Galvin, E; Hol, J; Klein, J; Ubben, JF; Verbrugge, SJ, 2010) |
| "Modafinil is a stimulant with a selective site of action in the brain that is better tolerated than traditional stimulants, such as methylphenidate." | 2.74 | Modafinil for the treatment of fatigue in lung cancer: a pilot study. ( Booden, D; Dhillan, R; Fife, K; Forbes, K; Spathis, A; Vrotsou, K, 2009) |
| "Armodafinil was well tolerated." | 2.73 | Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. ( Arora, S; Black, JE; Hirshkowitz, M; Niebler, G; Roth, T; Wesnes, K, 2007) |
| "Modafinil is a wake-promoting agent approved by the Federal Drug Administration for the treatment of narcolepsy." | 2.71 | A prospective trial of modafinil as an adjunctive treatment of major depression. ( DeBattista, C; Ghebremichael, R; Lembke, A; Poirier, J; Solvason, HB, 2004) |
| "Fatigue is a common symptom experienced by people with cancer and other long-term, non-malignant conditions." | 2.61 | The holistic management of fatigue within palliative care. ( Dean, A, 2019) |
| "Trial evidence for treating fatigue as a manifestation of sarcoidosis is limited and requires further investigation." | 2.55 | Managing fatigue in sarcoidosis - A systematic review of the evidence. ( Atkins, C; Wilson, AM, 2017) |
| "Fatigue is a common and disabling symptom in people with a primary brain tumour (PBT)." | 2.53 | Interventions for the management of fatigue in adults with a primary brain tumour. ( Armstrong, T; Bulbeck, H; Cachia, D; Day, J; Katz, LH; Rooney, AG; Tremont, I; Wefel, J; Yust-Katz, S, 2016) |
| "Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions." | 2.48 | Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012) |
| "Fatigue is a common and potentially debilitating symptom of neuromuscular disease (NMD)." | 2.46 | Assessment and management of fatigue in neuromuscular disease. ( Carter, GT; Lou, JS; Weiss, MD, 2010) |
| "There is no specific treatment for fatigue in PBC, but modafinil has shown some potential beneficial effects, such as increased energy levels and decreased total sleep time." | 2.46 | Fatigue in primary biliary cirrhosis. ( Abbas, G; Jorgensen, RA; Lindor, KD, 2010) |
| "Methylphenidate has been studied most and is effective and well tolerated despite common side effects." | 2.44 | Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. ( Alici, Y; Breitbart, W, 2008) |
| "Fatigue is among the most commonly reported symptoms of patients with cancer, with prevalence exceeding 60% in many studies." | 2.43 | Management of cancer-related fatigue. ( Hickok, JT; Morrow, GR; Mustian, K; Roscoe, JA; Shelke, AR, 2005) |
| " Approaches to the management of residual symptoms include addressing treatment-emergent side effects and co-morbid conditions, optimizing antidepressant dosing and using augmentation therapy." | 2.43 | Pharmacological approaches to the treatment of residual symptoms. ( Fava, M, 2006) |
| "Fatigue and sleepiness (hypersomnia) are symptoms that are highly prevalent in patients with major depressive disorder (MDD)." | 2.43 | Symptoms of fatigue and sleepiness in major depressive disorder. ( Baldwin, DS; Papakostas, GI, 2006) |
| "Modafinil has been shown to be effective in some studies, and amantadine is an alternative for patients who do not respond to or cannot tolerate modafinil." | 2.42 | Management of fatigue in patients with multiple sclerosis. ( Zifko, UA, 2004) |
| "Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1." | 2.41 | Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001) |
| "Fatigue is a frequently reported and disabling symptom in patients with systemic lupus erythematosus (SLE)." | 1.62 | Improvement of lupus-associated fatigue with modafinil: Report of two cases. ( Korsten, P; Piantoni, S, 2021) |
| "Fatigue, excessive daytime somnolence (EDS), and depression can delay their recovery and potentially worsen outcomes." | 1.43 | The Use of Modafinil in the Intensive Care Unit. ( Gajewski, M; Weinhouse, G, 2016) |
| "Modafinil was efficacious in increasing wheel running in the doxorubicin group." | 1.39 | A clinically translatable mouse model for chemotherapy-related fatigue. ( Fey, EG; Lyng, GD; Sonis, ST; Zombeck, JA, 2013) |
| "IFN-alpha-induced depression is presumed to be composed of two overlapping syndromes: a depression-specific syndrome characterized by depressed mood, anxiety, and cognitive complaints, and a neurovegetative syndrome consisting of fatigue, anorexia, somatic pain complaints, and psychomotor retardation [1]." | 1.34 | Modafinil's use in combating interferon-induced fatigue. ( Balan, V; Krahn, LE; Martin, KA; Rosati, MJ, 2007) |
| "The Fatigue Impact Scale for Daily Use (D-FIS) is an eight-item instrument designed to measure subjective daily experience of fatigue." | 1.34 | Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). ( Antigüedad, AR; Benito-León, J; de Andrés, C; Frades, B; Huete-Antón, B; Martínez-Ginés, ML; Martínez-Martín, P; Meca-Lallana, JE; Rodríguez-García, E; Ruiz-Martínez, J, 2007) |
| "Modafinil is a wakefulness-promoting agent that the FDA has approved for the treatment of excessive daytime sleepiness associated with narcolepsy." | 1.32 | Modafinil for the treatment of pain-associated fatigue: review and case report. ( Cole, B; Cutler, RB; Fishbain, DA; Lewis, J; Rosomoff, HL; Steele-Rosomoff, R, 2004) |
| "Fatigue is one of the most frequent and disabling symptoms in multiple sclerosis (MS) patients." | 1.32 | [Modafinil and fatigue in multiple sclerosis]. ( Montalbán, X; Téllez, N, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.60) | 18.2507 |
| 2000's | 74 (44.05) | 29.6817 |
| 2010's | 75 (44.64) | 24.3611 |
| 2020's | 18 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, R | 1 |
| Bruera, E | 1 |
| Sanatani, M | 1 |
| Chiu, L | 1 |
| Prsic, E | 1 |
| Boldt, G | 1 |
| Lock, M | 1 |
| Cocco, E | 1 |
| Fadda, P | 1 |
| Porter, AB | 1 |
| Liu, H | 1 |
| Kohli, S | 2 |
| Cerhan, JL | 1 |
| Sloan, J | 1 |
| McMurray, RP | 1 |
| Le-Rademacher, J | 1 |
| Loprinzi, CL | 2 |
| Villano, JL | 1 |
| Kizilbash, SH | 1 |
| Mehta, MP | 1 |
| Jaeckle, KA | 1 |
| Brown, PD | 4 |
| Day, J | 5 |
| Yust-Katz, S | 2 |
| Cachia, D | 2 |
| Wefel, J | 2 |
| Tremont Lukats, IW | 1 |
| Bulbeck, H | 2 |
| Rooney, AG | 2 |
| Wingelaar-Jagt, YQ | 3 |
| Wingelaar, TT | 1 |
| Riedel, WJ | 3 |
| Ramaekers, JG | 3 |
| Kirkman, MA | 3 |
| Gehring, K | 3 |
| Zienius, K | 3 |
| Grosshans, D | 3 |
| Taphoorn, M | 3 |
| Li, J | 3 |
| Bottenheft, C | 2 |
| Sandford, A | 1 |
| Haywood, A | 1 |
| Rickett, K | 1 |
| Good, P | 1 |
| Khan, S | 1 |
| Foster, K | 1 |
| Hardy, JR | 1 |
| Kratz, AL | 1 |
| Alschuler, KN | 1 |
| Ehde, DM | 1 |
| von Geldern, G | 1 |
| Little, R | 1 |
| Kulkarni, S | 1 |
| Pickup, K | 1 |
| Braley, TJ | 1 |
| Dean, A | 1 |
| McElhiney, MC | 4 |
| Rabkin, JG | 5 |
| Daughters, SB | 1 |
| Timperlake, EC | 1 |
| Wainberg, ML | 1 |
| Cross, DB | 1 |
| Tiu, J | 1 |
| Medicherla, C | 1 |
| Ishida, K | 1 |
| Lord, A | 1 |
| Czeisler, B | 1 |
| Wu, C | 1 |
| Golub, D | 1 |
| Karoub, A | 1 |
| Hernandez, C | 1 |
| Yaghi, S | 1 |
| Torres, J | 1 |
| Schallhorn, CS | 1 |
| Sholtes, D | 1 |
| Kravitz, HM | 1 |
| Deka, A | 1 |
| Westrick, J | 1 |
| Fogg, LF | 1 |
| Gottlieb, M | 1 |
| Bajorek, B | 1 |
| Gao, L | 1 |
| Lillicrap, T | 4 |
| Bivard, A | 5 |
| Garcia-Esperon, C | 2 |
| Parsons, M | 2 |
| Spratt, N | 1 |
| Holliday, E | 2 |
| Levi, C | 1 |
| Repantis, D | 1 |
| Bovy, L | 1 |
| Ohla, K | 1 |
| Kühn, S | 1 |
| Dresler, M | 1 |
| Nourbakhsh, B | 2 |
| Revirajan, N | 2 |
| Morris, B | 1 |
| Cordano, C | 1 |
| Creasman, J | 1 |
| Manguinao, M | 1 |
| Krysko, K | 1 |
| Rutatangwa, A | 1 |
| Auvray, C | 1 |
| Aljarallah, S | 1 |
| Jin, C | 1 |
| Mowry, E | 1 |
| McCulloch, C | 1 |
| Waubant, E | 3 |
| Bourdette, D | 1 |
| Korsten, P | 1 |
| Piantoni, S | 1 |
| Deb, U | 1 |
| Mukhopadhyay, S | 1 |
| Bhattacharya, B | 1 |
| Banerjee, S | 1 |
| Biswas, S | 1 |
| Ehlert, AM | 1 |
| Wilson, PB | 1 |
| Krystal, AD | 1 |
| Preud'homme, XA | 1 |
| Krishnamurthy, V | 2 |
| Attia, J | 2 |
| Pagram, H | 1 |
| Nilsson, M | 2 |
| Levi, CR | 4 |
| Bergin, ART | 1 |
| Hovey, E | 2 |
| Lloyd, A | 2 |
| Marx, G | 2 |
| Parente, P | 2 |
| Rapke, T | 2 |
| de Souza, P | 2 |
| Shangyan, H | 1 |
| Kuiqing, L | 1 |
| Yumin, X | 1 |
| Jie, C | 1 |
| Weixiong, L | 1 |
| Gibbons, C | 1 |
| Pagnini, F | 1 |
| Friede, T | 1 |
| Young, CA | 1 |
| Pacheco, RL | 1 |
| Latorraca, COC | 1 |
| da Silva, LDGM | 1 |
| Ferreira, DBGM | 1 |
| Fernandes, CAA | 1 |
| Hosni, ND | 1 |
| Cabrera Martimbianco, AL | 1 |
| Vianna Pachito, D | 1 |
| Riera, R | 1 |
| Visser, MM | 2 |
| Maréchal, B | 1 |
| Goodin, P | 2 |
| Lillicrap, TP | 1 |
| Spratt, NJ | 2 |
| Parsons, MW | 3 |
| Ooi, T | 1 |
| Wong, SH | 1 |
| See, B | 1 |
| Laberge, L | 1 |
| Gagnon, C | 1 |
| Dauvilliers, Y | 2 |
| Younes, DM | 1 |
| Asch, F | 1 |
| Rubin, SM | 1 |
| Boele, FW | 1 |
| Douw, L | 1 |
| de Groot, M | 1 |
| van Thuijl, HF | 1 |
| Cleijne, W | 1 |
| Heimans, JJ | 1 |
| Taphoorn, MJ | 1 |
| Reijneveld, JC | 1 |
| Klein, M | 1 |
| McElhiney, M | 3 |
| Rabkin, J | 2 |
| Van Gorp, W | 2 |
| Rabkin, R | 6 |
| Barsevick, AM | 1 |
| Irwin, MR | 1 |
| Hinds, P | 1 |
| Miller, A | 1 |
| Berger, A | 1 |
| Jacobsen, P | 1 |
| Ancoli-Israel, S | 1 |
| Reeve, BB | 1 |
| Mustian, K | 2 |
| O'Mara, A | 1 |
| Lai, JS | 1 |
| Fisch, M | 1 |
| Cella, D | 1 |
| Launois, SH | 1 |
| Tamisier, R | 1 |
| Lévy, P | 1 |
| Pépin, JL | 1 |
| Sheng, P | 1 |
| Hou, L | 1 |
| Wang, X | 2 |
| Huang, C | 1 |
| Yu, M | 1 |
| Han, X | 1 |
| Dong, Y | 1 |
| Ledinek, AH | 1 |
| Sajko, MC | 1 |
| Rot, U | 1 |
| Zombeck, JA | 1 |
| Fey, EG | 1 |
| Lyng, GD | 1 |
| Sonis, ST | 1 |
| Hill, A | 1 |
| Bonaventura, A | 1 |
| Michele, A | 1 |
| Craft, P | 1 |
| Abdi, E | 1 |
| Spathis, A | 3 |
| Fife, K | 2 |
| Blackhall, F | 1 |
| Dutton, S | 1 |
| Bahadori, R | 1 |
| Wharton, R | 1 |
| O'Brien, M | 1 |
| Stone, P | 2 |
| Benepal, T | 1 |
| Bates, N | 1 |
| Wee, B | 1 |
| Ruddy, KJ | 1 |
| Barton, D | 1 |
| Denlinger, CS | 1 |
| Ligibel, JA | 1 |
| Are, M | 1 |
| Baker, KS | 1 |
| Demark-Wahnefried, W | 1 |
| Friedman, DL | 1 |
| Goldman, M | 1 |
| Jones, L | 1 |
| King, A | 1 |
| Ku, GH | 1 |
| Kvale, E | 1 |
| Langbaum, TS | 1 |
| Leonardi-Warren, K | 1 |
| McCabe, MS | 1 |
| Melisko, M | 1 |
| Montoya, JG | 1 |
| Mooney, K | 1 |
| Morgan, MA | 1 |
| Moslehi, JJ | 1 |
| O'Connor, T | 1 |
| Overholser, L | 1 |
| Paskett, ED | 1 |
| Raza, M | 1 |
| Syrjala, KL | 1 |
| Urba, SG | 1 |
| Wakabayashi, MT | 1 |
| Zee, P | 1 |
| McMillian, NR | 1 |
| Freedman-Cass, DA | 1 |
| Andrade, C | 1 |
| Kisely, S | 1 |
| Monteiro, I | 1 |
| Rao, S | 1 |
| Goold, I | 1 |
| Maslen, H | 1 |
| Berenson, JR | 1 |
| Yellin, O | 1 |
| Shamasunder, HK | 1 |
| Chen, CS | 1 |
| Charu, V | 1 |
| Woliver, TB | 1 |
| Sanani, S | 1 |
| Schlutz, M | 1 |
| Nassir, Y | 1 |
| Swift, RA | 1 |
| Andreu-Vieyra, C | 1 |
| Vescio, R | 1 |
| Gajewski, M | 1 |
| Weinhouse, G | 1 |
| Page, BR | 1 |
| Shaw, EG | 1 |
| Lu, L | 1 |
| Bryant, D | 1 |
| Grisell, D | 1 |
| Lesser, GJ | 1 |
| Monitto, DC | 1 |
| Naughton, MJ | 1 |
| Rapp, SR | 1 |
| Savona, SR | 1 |
| Shah, S | 1 |
| Case, D | 1 |
| Chan, MD | 1 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 1 |
| Radbruch, L | 3 |
| Lecendreux, M | 1 |
| Lavault, S | 1 |
| Lopez, R | 1 |
| Inocente, CO | 1 |
| Konofal, E | 1 |
| Cortese, S | 1 |
| Franco, P | 1 |
| Arnulf, I | 1 |
| Meyer, F | 1 |
| Freeman, MP | 1 |
| Petrillo, L | 1 |
| Barsky, M | 1 |
| Galvan, T | 1 |
| Kim, S | 1 |
| Cohen, L | 1 |
| Joffe, H | 1 |
| Qu, D | 1 |
| Zhang, Z | 1 |
| Yu, X | 1 |
| Zhao, J | 1 |
| Qiu, F | 1 |
| Huang, J | 1 |
| Flindall, I | 1 |
| Leff, DR | 1 |
| Goodship, J | 1 |
| Sugden, C | 1 |
| Darzi, A | 1 |
| Poulsen, MB | 1 |
| Damgaard, B | 1 |
| Zerahn, B | 1 |
| Overgaard, K | 1 |
| Rasmussen, RS | 1 |
| Heckler, CE | 2 |
| Garland, SN | 1 |
| Peoples, AR | 1 |
| Perlis, ML | 1 |
| Shayne, M | 1 |
| Morrow, GR | 5 |
| Kamen, C | 1 |
| Hoefler, J | 1 |
| Roscoe, JA | 4 |
| Ford-Johnson, L | 1 |
| DeLuca, J | 1 |
| Zhang, J | 1 |
| Elovic, E | 1 |
| Lengenfelder, J | 1 |
| Chiaravalloti, ND | 1 |
| Conley, CC | 1 |
| Kamen, CS | 1 |
| Janelsins, MC | 1 |
| Peppone, LJ | 2 |
| Scalzo, AJ | 1 |
| Gross, H | 1 |
| Dakhil, S | 1 |
| Mustian, KM | 2 |
| Palesh, OG | 2 |
| Lee, EQ | 1 |
| Muzikansky, A | 1 |
| Drappatz, J | 1 |
| Kesari, S | 1 |
| Wong, ET | 1 |
| Fadul, CE | 1 |
| Reardon, DA | 1 |
| Norden, AD | 1 |
| Nayak, L | 1 |
| Rinne, ML | 1 |
| Alexander, BM | 1 |
| Arvold, ND | 1 |
| Doherty, L | 1 |
| Stefanik, J | 1 |
| LaFrankie, D | 1 |
| Ruland, SF | 1 |
| Pulverenti, J | 1 |
| Smith, KH | 1 |
| Gaffey, SC | 1 |
| Hammond, S | 1 |
| Wen, PY | 1 |
| Katz, LH | 1 |
| Tremont, I | 1 |
| Armstrong, T | 1 |
| Atkins, C | 1 |
| Wilson, AM | 1 |
| Parker, RS | 1 |
| Parker, P | 1 |
| Alfano, CM | 1 |
| Heckler, C | 2 |
| Kleckner, AS | 1 |
| Kleckner, IR | 1 |
| Leach, CR | 1 |
| Mohr, D | 1 |
| Piper, BF | 1 |
| Scarpato, J | 1 |
| Smith, T | 1 |
| Sprod, LK | 1 |
| Miller, SM | 1 |
| Russo, MB | 1 |
| Arnett, MV | 1 |
| Thomas, ML | 1 |
| Caldwell, JA | 3 |
| Hampton, T | 1 |
| Ballard, RD | 1 |
| McNeil, C | 1 |
| Ramsey, CS | 1 |
| Werchan, PM | 1 |
| Isdahl, WM | 1 |
| Fischer, J | 1 |
| Gibbons, JA | 1 |
| Breitbart, W | 1 |
| Alici, Y | 1 |
| Saavedra-Velez, C | 1 |
| Yusim, A | 1 |
| Anbarasan, D | 1 |
| Lindenmayer, JP | 1 |
| Rosenthal, TC | 1 |
| Majeroni, BA | 1 |
| Pretorius, R | 1 |
| Malik, K | 1 |
| Ian Gan, S | 1 |
| de Jongh, M | 1 |
| Kaplan, MM | 2 |
| Gordon, PH | 1 |
| Chew, S | 1 |
| Mitsumoto, H | 1 |
| Dhillan, R | 1 |
| Booden, D | 1 |
| Forbes, K | 1 |
| Vrotsou, K | 1 |
| Fisher, SG | 1 |
| Tra, Y | 1 |
| Adams, MJ | 1 |
| Mapstone, ME | 1 |
| Wesnes, KA | 1 |
| Cooper, MR | 1 |
| Bird, HM | 1 |
| Steinberg, M | 1 |
| Lange, R | 1 |
| Volkmer, M | 1 |
| Heesen, C | 2 |
| Liepert, J | 1 |
| Blackhall, L | 1 |
| Petroni, G | 1 |
| Shu, J | 1 |
| Baum, L | 1 |
| Farace, E | 1 |
| Lundorff, LE | 1 |
| Jønsson, BH | 1 |
| Sjøgren, P | 1 |
| Brioschi, A | 1 |
| Gramigna, S | 1 |
| Werth, E | 2 |
| Staub, F | 1 |
| Ruffieux, C | 1 |
| Bassetti, C | 1 |
| Schluep, M | 1 |
| Annoni, JM | 1 |
| Freudenreich, O | 1 |
| Henderson, DC | 1 |
| Macklin, EA | 1 |
| Evins, AE | 1 |
| Fan, X | 1 |
| Cather, C | 1 |
| Walsh, JP | 1 |
| Goff, DC | 1 |
| Galvin, E | 1 |
| Boesjes, H | 1 |
| Hol, J | 1 |
| Ubben, JF | 1 |
| Klein, J | 1 |
| Verbrugge, SJ | 1 |
| Littleton, ET | 1 |
| Hobart, JC | 1 |
| Palace, J | 1 |
| Rose, SH | 1 |
| Curry, TB | 1 |
| Lou, JS | 1 |
| Weiss, MD | 1 |
| Carter, GT | 1 |
| Kanjwal, K | 1 |
| Saeed, B | 1 |
| Karabin, B | 1 |
| Kanjwal, Y | 1 |
| Grubb, BP | 1 |
| Brown, JN | 1 |
| Howard, CA | 1 |
| Kemp, DW | 1 |
| Abbas, G | 1 |
| Jorgensen, RA | 1 |
| Lindor, KD | 1 |
| Black, W | 1 |
| Hoey, P | 1 |
| Mayze, T | 1 |
| McGrath, PJ | 1 |
| Hardy, T | 1 |
| MacDonald, C | 1 |
| Jones, DE | 2 |
| Newton, JL | 2 |
| Jean-Pierre, P | 1 |
| Mohile, S | 1 |
| Janelsins, M | 1 |
| Peppone, L | 1 |
| Hemstad, A | 1 |
| Esparaz, BT | 1 |
| Hopkins, JO | 1 |
| Gore, RK | 1 |
| Webb, TS | 1 |
| Hermes, ED | 1 |
| Wirz, S | 1 |
| Nadstawek, J | 1 |
| Kühn, KU | 1 |
| Vater, S | 1 |
| Junker, U | 1 |
| Wartenberg, HC | 1 |
| Peuckmann, V | 1 |
| Elsner, F | 2 |
| Krumm, N | 1 |
| Trottenberg, P | 1 |
| Dasheiff, RM | 1 |
| Kaiser, PR | 1 |
| Valko, PO | 1 |
| Thomann, J | 1 |
| Meier, J | 1 |
| Stocker, R | 1 |
| Bassetti, CL | 1 |
| Baumann, CR | 1 |
| Frost, J | 1 |
| Okun, S | 1 |
| Vaughan, T | 1 |
| Heywood, J | 1 |
| Wicks, P | 1 |
| Portela, MA | 1 |
| Rubiales, AS | 1 |
| Centeno, C | 1 |
| Drabiak-Syed, K | 1 |
| Möller, F | 1 |
| Poettgen, J | 1 |
| Broemel, F | 1 |
| Neuhaus, A | 1 |
| Daumer, M | 1 |
| Kirshbaum, M | 1 |
| Phillips, JB | 1 |
| Simmons, RG | 1 |
| Arnold, RD | 1 |
| Estrada, A | 1 |
| Kelley, AM | 1 |
| Webb, CM | 1 |
| Athy, JR | 1 |
| Crowley, JS | 1 |
| Niepel, G | 1 |
| Bibani, RH | 1 |
| Vilisaar, J | 1 |
| Langley, RW | 1 |
| Bradshaw, CM | 1 |
| Szabadi, E | 1 |
| Constantinescu, CS | 2 |
| Lower, EE | 1 |
| Malhotra, A | 1 |
| Surdulescu, V | 1 |
| Baughman, RP | 1 |
| Induruwa, I | 1 |
| Gran, B | 1 |
| Bruce, J | 1 |
| Hancock, L | 1 |
| Roberg, B | 1 |
| Brown, A | 1 |
| Henkelman, E | 1 |
| Lynch, S | 1 |
| Zifko, UA | 2 |
| Rupp, M | 1 |
| Schwarz, S | 1 |
| Zipko, HT | 1 |
| Maida, EM | 1 |
| Billiard, M | 1 |
| Simons, J | 1 |
| Li, YF | 1 |
| Zhan, H | 1 |
| Xin, YM | 1 |
| Tang, GX | 1 |
| Wei, SH | 1 |
| Li, T | 1 |
| DeBattista, C | 4 |
| Doghramji, K | 1 |
| Menza, MA | 1 |
| Rosenthal, MH | 2 |
| Fieve, RR | 1 |
| Becker, PM | 1 |
| Schwartz, JR | 1 |
| Feldman, NT | 1 |
| Hughes, RJ | 2 |
| Lembke, A | 1 |
| Solvason, HB | 2 |
| Ghebremichael, R | 1 |
| Poirier, J | 1 |
| Larijani, GE | 2 |
| Goldberg, ME | 2 |
| Hojat, M | 1 |
| Khaleghi, B | 1 |
| Dunn, JB | 1 |
| Marr, AT | 1 |
| Ninan, PT | 2 |
| Hassman, HA | 1 |
| Glass, SJ | 1 |
| McManus, FC | 1 |
| Wesensten, NJ | 1 |
| Belenky, G | 1 |
| Thorne, DR | 1 |
| Kautz, MA | 1 |
| Balkin, TJ | 1 |
| Baranski, JV | 1 |
| Pigeau, R | 1 |
| Dinich, P | 1 |
| Jacobs, I | 1 |
| Fishbain, DA | 1 |
| Cutler, RB | 1 |
| Lewis, J | 1 |
| Cole, B | 1 |
| Rosomoff, HL | 1 |
| Steele-Rosomoff, R | 1 |
| Ashton, AK | 1 |
| Schwartz, TL | 2 |
| Azhar, N | 1 |
| Cole, K | 1 |
| Hopkins, G | 1 |
| Nihalani, N | 1 |
| Simionescu, M | 1 |
| Husain, J | 1 |
| Jones, N | 1 |
| Caldwell, JL | 2 |
| Smith, JK | 1 |
| Brown, DL | 1 |
| Téllez, N | 1 |
| Montalbán, X | 1 |
| Ferrando, SJ | 1 |
| Makela, EH | 1 |
| Fava, M | 3 |
| Thase, ME | 2 |
| Florence, G | 1 |
| Riondet, L | 1 |
| Serra, A | 1 |
| Etienne, X | 1 |
| Huart, B | 1 |
| van Beers, P | 2 |
| Bonneau, D | 1 |
| Gomez-Merino, D | 1 |
| Drogou, C | 1 |
| Pradeau, P | 1 |
| Schwid, SR | 1 |
| Murray, TJ | 1 |
| Stankoff, B | 1 |
| Confavreux, C | 1 |
| Edan, G | 1 |
| Debouverie, M | 2 |
| Rumbach, L | 1 |
| Moreau, T | 1 |
| Pelletier, J | 1 |
| Lubetzki, C | 1 |
| Clanet, M | 1 |
| Shelke, AR | 1 |
| Hickok, JT | 1 |
| Sevy, S | 1 |
| Alvir, J | 1 |
| Meyer, S | 1 |
| Visweswaraiah, H | 1 |
| Gunduz-Bruce, H | 1 |
| Schooler, NR | 1 |
| Chan, KM | 1 |
| Strohschein, FJ | 1 |
| Rydz, D | 1 |
| Allidina, A | 1 |
| Shuaib, A | 1 |
| Westbury, CF | 1 |
| Oskooilar, N | 1 |
| Bonis, PA | 1 |
| Arora, S | 2 |
| Pittion, S | 1 |
| Boërio, D | 1 |
| Lefaucheur, JP | 1 |
| Hogrel, JY | 1 |
| Créange, A | 1 |
| Batéjat, D | 1 |
| Coste, O | 1 |
| Lagarde, D | 1 |
| Piérard, C | 1 |
| Beaumont, M | 1 |
| Nasr, S | 1 |
| Wendt, B | 1 |
| Steiner, K | 1 |
| Baldwin, DS | 1 |
| Papakostas, GI | 1 |
| Hirshkowitz, M | 1 |
| Black, JE | 1 |
| Wesnes, K | 1 |
| Niebler, G | 1 |
| Roth, T | 1 |
| Reineke-Bracke, H | 1 |
| Nagels, G | 1 |
| D'hooghe, MB | 1 |
| Vleugels, L | 1 |
| Kos, D | 1 |
| Despontin, M | 1 |
| De Deyn, PP | 1 |
| Rayancha, S | 1 |
| Rashid, A | 1 |
| Chlebowksi, S | 1 |
| Chilton, M | 1 |
| Morell, M | 1 |
| Martin, KA | 1 |
| Krahn, LE | 1 |
| Balan, V | 1 |
| Rosati, MJ | 1 |
| Carrieri, PB | 1 |
| de Leva, MF | 1 |
| Carrieri, M | 1 |
| Buongiorno, M | 1 |
| Vasconcelos, OM | 1 |
| Prokhorenko, OA | 1 |
| Salajegheh, MK | 1 |
| Kelley, KF | 1 |
| Livornese, K | 1 |
| Olsen, CH | 1 |
| Vo, AH | 1 |
| Dalakas, MC | 1 |
| Halstead, LS | 1 |
| Jabbari, B | 1 |
| Campbell, WW | 1 |
| Lam, JY | 1 |
| Freeman, MK | 1 |
| Cates, ME | 1 |
| Benito-León, J | 1 |
| Martínez-Martín, P | 1 |
| Frades, B | 1 |
| Martínez-Ginés, ML | 1 |
| de Andrés, C | 1 |
| Meca-Lallana, JE | 1 |
| Antigüedad, AR | 1 |
| Huete-Antón, B | 1 |
| Rodríguez-García, E | 1 |
| Ruiz-Martínez, J | 1 |
| Dunlop, BW | 1 |
| Crits-Christoph, P | 1 |
| Evans, DL | 1 |
| Hirschowitz, J | 1 |
| Rickels, K | 1 |
| Garlow, SJ | 1 |
| Gallop, RJ | 1 |
| Eaton, C | 1 |
| Rison, RA | 1 |
| Akerstedt, T | 1 |
| Ficca, G | 1 |
| Hohlfeld, R | 1 |
| Willoughby, E | 1 |
| Rammohan, KW | 1 |
| Rosenberg, JH | 1 |
| Lynn, DJ | 1 |
| Blumenfeld, AM | 1 |
| Pollak, CP | 1 |
| Nagaraja, HN | 1 |
| Krupp, LB | 1 |
| Christodoulou, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma[NCT01781468] | Phase 3 | 328 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis[NCT03185065] | Phase 3 | 141 participants (Actual) | Interventional | 2017-10-04 | Completed | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Managing Fatigue: The Individual Program in People Living With Parkinson's Disease- A Protocol for a Feasibility Study[NCT04267107] | 23 participants (Actual) | Interventional | 2020-11-02 | Completed | |||
| Quantifying Fatigue of the Respiratory and Swallowing Musculature in Patients With Amyotrophic Lateral Sclerosis[NCT04468191] | 0 participants (Actual) | Interventional | 2021-02-10 | Withdrawn (stopped due to COVID-19 pandemic restrictions for data collection) | |||
| Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306] | 60 participants (Anticipated) | Interventional | 2023-05-17 | Recruiting | |||
| Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329] | 80 participants (Anticipated) | Interventional | 2018-05-13 | Recruiting | |||
| A Prospective, Randomised, Double-Blind, Placebo-Controlled Phase III Study of Modafinil to Improve Fatigue and Quality of Life in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer[NCT00917748] | Phase 3 | 84 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Modafinil to Improve Fatiguability (MODIFY): Modafinil vs. Placebo Vanguard RCT[NCT05333250] | Phase 3 | 40 participants (Anticipated) | Interventional | 2024-04-30 | Not yet recruiting | ||
| Modafinil for the Treatment of Fatigue in Lung Cancer: a Multicentre, Randomised, Double-blinded, Placebo-controlled Trial[NCT00829322] | Phase 4 | 208 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Treatment of Post Stroke Fatigue With Modafinil, Effect on Rehabilitation, Fatigue and Bonemass Index[NCT01800097] | Phase 3 | 41 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Slow recruitment) | ||
| Clinical Study on Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Adjuvant Chemotherapy[NCT06137833] | 92 participants (Anticipated) | Interventional | 2023-11-27 | Not yet recruiting | |||
| Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder: A Pilot Study[NCT00838227] | Phase 2 | 0 participants (Actual) | Interventional | 2008-02-29 | Withdrawn (stopped due to No source of funding to implement the study.) | ||
| Randomized Controlled Study to Evaluate the Effects of Modafinil in Cancer Related Fatigue in Patients Undergoing Radiation Therapy[NCT01440621] | Phase 3 | 217 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Amantadine for Neuroenhancement in Acute Patients Study - A Prospective Pilot Proof of Concept Phase IIb Study in Intensive and Intermediate Care Unit Patients[NCT05479032] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia[NCT00573417] | Phase 4 | 40 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea[NCT02494102] | Phase 4 | 105 participants (Actual) | Interventional | 2016-02-29 | Terminated | ||
| Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS[NCT01158443] | Phase 4 | 46 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Modafinil Treatment for Fatigue in HIV+ Patients[NCT00118378] | Phase 4 | 115 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of The Effect Of Modafinil On Fatigue In Cancer Patients Receiving Chemotherapy[NCT00042848] | Phase 3 | 837 participants (Anticipated) | Interventional | 2002-08-31 | Completed | ||
| Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093] | 40 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020] | 100 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Does Modafinil Have Pro-cognitive Effects in Those With Residual Cognitive Impairment Despite Remitted Depression?[NCT03620253] | Phase 3 | 9 participants (Actual) | Interventional | 2018-10-15 | Terminated (stopped due to Principal Investigator left study site) | ||
| The Effect of Caffeine on the Narcoleptic Patients Randomized Controlled Clinical Trial[NCT02832336] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2016-10-01 | Completed | ||
| Armodafinil Treatment for Fatigue in HIV+ Patients[NCT00737204] | Phase 4 | 70 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820] | 105 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Comparison Between the Effects on Fatigue of Aerobic Training Versus Balance Training in Patients With Multiple Sclerosis: a Randomised Crossover Trial.[NCT06051019] | 39 participants (Actual) | Interventional | 2016-02-17 | Completed | |||
| Randomized Controlled Trial of Exercise to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer[NCT02846389] | 24 participants (Actual) | Interventional | 2016-06-21 | Active, not recruiting | |||
| The Effects of EXOPULSE Mollii Suit on Motor Functions in Patients With Multiple Sclerosis (EXOSEP 2)[NCT05857280] | 36 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | |||
| Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea[NCT01563900] | 0 participants (Actual) | Interventional | 2012-02-29 | Withdrawn (stopped due to Was unable to recruit subjects) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The participant is presented with a page headed by a key that pairs the single digits 1-9 with nine symbols. Rows below contain only symbols, the subject's task is to orally report the correct number in the spaces below. After completing the first 10 items with guidance, the subject is timed to determine how many responses can be made in 90 seconds. Range score: not applicable. Higher scores mean a better outcome. Explored domain: Sustained attention and information processing speed. Each neuropsychological measure was converted to an age-normative z score using published normative data. Impaired SDMT performance was defined as falling one standard deviation or more below the normative mean. (NCT01781468)
Timeframe: Up to 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Arm I (150 mg Armodafinil) | 0.0 |
| Arm II (250 mg Armodafinil) | 0.3 |
| Arm III (Placebo) | 0.0 |
A response is defined as an improvement of 2 points on the 0-10 scale of the usual fatigue on the Brief Fatigue Inventory (BFI). The number of participants with a response in terms of a clinically meaningful improvement in patient-reported fatigue at 4 weeks Scale: 0 (No fatigue) - 10 (As bad as you can imagine) Interpretation: higher scores mean a worse outcome (NCT01781468)
Timeframe: Up to 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (150 mg Armodafinil) | 37 |
| Arm II (250 mg Armodafinil) | 31 |
| Arm III (Placebo) | 30 |
The number of participants who experienced at least one grade 3 or higher adverse events deemed at least possibly related to treatment via the CTCAE version 4.0 (NCT01781468)
Timeframe: Up to 8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (150 mg Armodafinil) | 6 |
| Arm II (250 mg Armodafinil) | 8 |
| Arm III (Placebo) | 3 |
"A response is defined as an improvement of 2 points on the 0-10 scale of the usual fatigue on the Brief Fatigue Inventory (BFI). The number of participants with a response in terms of a clinically meaningful improvement in patient-reported fatigue at 8 weeks.~Scale: 0 (No fatigue) - 10 (As bad as you can imagine) Interpretation: higher scores mean a worse outcome" (NCT01781468)
Timeframe: At 8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (150 mg Armodafinil) | 29 |
| Arm II (250 mg Armodafinil) | 27 |
| Arm III (Placebo) | 29 |
Quality of life: Linear Analogue Self Assessment (LASA) will be analyzed comparing the total score for each treatment testing for change from baseline to four and eight weeks. Linear Analogue Self Assessment (LASA) is a 12 global QOL tool to which measures 10 subscales: overall QOL, physical well-being, fatigue, frequency and severity of pain, as well as social functioning and spiritual, emotional and mental well-being. All subscales were converted to a scale of 0-100, with higher scores indicating better QOL. Total score is the average of all 10 subscales. (NCT01781468)
Timeframe: Up to 8 weeks
| Intervention | units on a scale (Median) | |
|---|---|---|
| Baseline to Week 4 | Baseline to Week 8 | |
| Arm I (150 mg Armodafinil) | 2.0 | 4.0 |
| Arm II (250 mg Armodafinil) | 0.5 | 3.0 |
| Arm III (Placebo) | 2.0 | 2.0 |
"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 39 |
| Amantadine | 41 |
| Modafinil | 55 |
| Methylphenidate | 55 |
ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 9.4 |
| Amantadine | 9.3 |
| Modafinil | 8.3 |
| Methylphenidate | 8.8 |
MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 40.6 |
| Amantadine | 41.3 |
| Modafinil | 39.0 |
| Methylphenidate | 38.6 |
Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 53.1 |
| Amantadine | 53.0 |
| Modafinil | 52.5 |
| Methylphenidate | 52.0 |
Length of time of above compared between groups (NCT02494102)
Timeframe: 24 hours
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 53.5 |
| Modafinil | 61.0 |
Postanesthesia quality recovery scale (PQRS). Component and aggregate scoring on the scale. Measures physiology, nociceptive, emotional activities of daily living cognitive and overall patient perspective. The scale is dimensionless and the aggregate of all individually tested dimensions is scaled from 17-65. A higher value implies improved postanesthesia recovery. Mean difference was assessed in each patient and aggregated thus patients with no difference between pre- and post-operative scores were zeroed (received a zero score if the difference was zero). A negative value was associated with worse outcome. (NCT02494102)
Timeframe: baseline and 6 hours after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -5.67 |
| Modafinil | -8.91 |
CD4 cell count is a laboratory marker providing an indication of immune functioning. Blood was drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of >= 100 cells. A higher number is associated with better immune functioning. (NCT00118378)
Timeframe: Measured at baseline and Week 4
| Intervention | Cells/mcL (Mean) | |
|---|---|---|
| Baseline CD4 cell count | Week 4 CD4 cell count | |
| Modafinil | 481 | 466 |
| Placebo | 459 | 482 |
The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9 to 63, with a higher value indicating greater impairment due to fatigue. (NCT00118378)
Timeframe: Measured at baseline and Week 4
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline FSS | Week 4 FSS | |
| Modafinil | 52 | 34 |
| Placebo | 52 | 43 |
"HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50-100,000 copies), this measure is presented in log10. We entered the log10 value of 1.69 when the laboratory result stated under 50 copies, which was the assay's lowest limit of detectability during the study." (NCT00118378)
Timeframe: Measured at baseline and Week 4
| Intervention | Log10 copies/mL (Mean) | |
|---|---|---|
| Baseline Log10 Viral Load | Week 4 Log10 Viral load | |
| Modafinil | 2.53 | 2.31 |
| Placebo | 2.41 | 2.30 |
The Role Function Scale includes 10 items drawn from the Short Form 36-item Health Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10 to 50. (NCT00118378)
Timeframe: Measured at baseline and Week 4
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline Role Function Scale | Week 4 Role Function Scale | |
| Modafinil | 39 | 22 |
| Placebo | 36 | 27 |
Cd4 cell count is a laboratory marker providing an indication of immune system functioning. Blood samples were drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of >=100 cells. A higher number is associated with better immune functioning. (NCT00737204)
Timeframe: Measured at baseline and Week 4
| Intervention | Cells/mcL (Mean) | |
|---|---|---|
| Baseline CD4 cell count | Week 4 CD4 cell count | |
| Armodafinil | 502 | 503 |
| Placebo | 450 | 445 |
The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9-63, with a higher score indicating greater impairment due to fatigue. (NCT00737204)
Timeframe: Measured at baseline and Weeks 4
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline FSS | Week 4 FSS | |
| Armodafinil | 52.6 | 25.8 |
| Placebo | 53.1 | 39.4 |
"HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50 - 100,000 copies), this measure is transformed to log10 values. We entered the log10 value of 1.69 when the laboratory result stated under 50 copies, which was the assay's lowest limit of detectability during the study." (NCT00737204)
Timeframe: Measured at baseline and Week 4
| Intervention | Log10 copies/mL (Mean) | |
|---|---|---|
| Baseline Log10 Viral Load | Week 4 Log10 Viral load | |
| Armodafinil | 2.17 | 2.15 |
| Placebo | 2.39 | 2.24 |
The Role Function Scale includes 10 items drawn from the Short Form 36-item Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10-50. (NCT00737204)
Timeframe: Measured at Baseline and Week 4
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline Role Function Scale | Week 4 Role Function Scale | |
| Armodafinil | 36.2 | 19.9 |
| Placebo | 37.8 | 28.3 |
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
43 reviews available for modafinil and Fatigue
| Article | Year |
|---|---|
Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis.
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Network M | 2023 |
Treatment of multiple sclerosis fatigue with the synthetic psychoactive drug modafinil.
Topics: Activities of Daily Living; Central Nervous System Stimulants; Fatigue; Humans; Modafinil; Multiple | 2022 |
Interventions for the management of fatigue in adults with a primary brain tumour.
Topics: Adult; Brain Neoplasms; Dextroamphetamine; Fatigue; Glioma; Humans; Modafinil | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Dexamethasone; Fatigue; Humans; Modafinil; Neoplasms; Qu | 2023 |
The holistic management of fatigue within palliative care.
Topics: Central Nervous System Stimulants; Chronic Disease; Cognitive Behavioral Therapy; Complementary Ther | 2019 |
Optimising sleep and performance during night float: A systematic review of evidence and implications for graduate medical education trainees.
Topics: Adaptation, Physiological; Attention; Caffeine; Education, Medical, Graduate; Energy Drinks; Fatigue | 2021 |
Stimulant Use as a Fatigue Countermeasure in Aviation.
Topics: Aerospace Medicine; Aviation; Central Nervous System Stimulants; Fatigue; Humans; Modafinil; Sleep D | 2021 |
Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue.
Topics: Adult; Benzhydryl Compounds; Cytochrome P-450 CYP3A Inducers; Fatigue; Humans; Middle Aged; Modafini | 2018 |
Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Benzhydryl Compounds; Breathing Exercises; Fatigue; Humans; Modafinil | 2018 |
Modafinil for poststroke patients: A systematic review.
Topics: Cognition; Fatigue; Humans; Modafinil; Quality of Life; Stroke; Wakefulness-Promoting Agents | 2019 |
Daytime sleepiness and myotonic dystrophy.
Topics: Age of Onset; Alternative Splicing; Benzhydryl Compounds; Brain Chemistry; Brain Stem; Combined Moda | 2013 |
Management of cognition and fatigue.
Topics: Animals; Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Cognition Disorders; Depression; D | 2013 |
On treatment but still sleepy: cause and management of residual sleepiness in obstructive sleep apnea.
Topics: Benzhydryl Compounds; Continuous Positive Airway Pressure; Depression; Disorders of Excessive Somnol | 2013 |
Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Depression; Disorders of Excessive Somnolence; Fatigue; Humans; Modafinil | 2013 |
Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Benzhydryl Compounds; Cognition; Fatigue; Female; Humans; Male; Middle | 2015 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
Psychotropic drugs for the management of cancer-related fatigue: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Psychotropic Drugs | 2016 |
Interventions for the management of fatigue in adults with a primary brain tumour.
Topics: Adult; Benzhydryl Compounds; Brain Neoplasms; Fatigue; Humans; Modafinil; Randomized Controlled Tria | 2016 |
Managing fatigue in sarcoidosis - A systematic review of the evidence.
Topics: Adalimumab; Antirheumatic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Exercise | 2017 |
The impact of sleep deprivation in military surgical teams: a systematic review.
Topics: Benzhydryl Compounds; Clinical Competence; Cognition; Fatigue; Health Personnel; Humans; Military Me | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Management of patients with obstructive sleep apnea.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive Airway Pressure; Fatigu | 2008 |
Pharmacologic treatment options for cancer-related fatigue: current state of clinical research.
Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Cholinesterase Inhib | 2008 |
Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
Topics: Affective Symptoms; Antipsychotic Agents; Arousal; Attention; Benzhydryl Compounds; Central Nervous | 2009 |
Fatigue: an overview.
Topics: Behavior Therapy; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Chronic Disease | 2008 |
Efficacy and safety of modafinil in the treatment of cancer-related fatigue.
Topics: Animals; Benzhydryl Compounds; Fatigue; Humans; Modafinil; Neoplasms; Randomized Controlled Trials a | 2009 |
Assessment and management of fatigue in neuromuscular disease.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Exercise; Fatigue; Humans; Modafinil; Muscl | 2010 |
Modafinil for the treatment of multiple sclerosis-related fatigue.
Topics: Animals; Benzhydryl Compounds; Fatigue; Humans; Modafinil; Multiple Sclerosis; Randomized Controlled | 2010 |
Fatigue in primary biliary cirrhosis.
Topics: Adipokines; Animals; Autonomic Nervous System; Benzhydryl Compounds; Cytokines; Diagnosis, Different | 2010 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney | 2010 |
The use of psychostimulants in cancer patients.
Topics: Adult; Antineoplastic Agents; Asthenia; Benzhydryl Compounds; Central Nervous System Stimulants; Chi | 2011 |
Pharmacologic treatments for fatigue associated with palliative care.
Topics: Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Evidence-Based Medicine; Fatigu | 2011 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
[Modafinil: pharmacology and therapeutic perspectives].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Fatigue; Humans; | 2003 |
Management of fatigue in patients with multiple sclerosis.
Topics: Amantadine; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Clinical | 2004 |
Management of cancer-related fatigue.
Topics: Antidepressive Agents; Benzhydryl Compounds; Depression; Fatigue; Glucocorticoids; Humans; Modafinil | 2005 |
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N | 2006 |
Pharmacological approaches to the treatment of residual symptoms.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Benzhydryl Compounds; Benzodiazepines; Central | 2006 |
Symptoms of fatigue and sleepiness in major depressive disorder.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Bupropion; Ce | 2006 |
Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants.
Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depression; Fatigue; | 2007 |
Alertness-enhancing drugs as a countermeasure to fatigue in irregular work hours.
Topics: Amphetamine; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Fatigue; Humans; Mod | 1997 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste | 2001 |
65 trials available for modafinil and Fatigue
| Article | Year |
|---|---|
Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial.
Topics: Adult; Aged; Benzhydryl Compounds; Double-Blind Method; Fatigue; Female; Glioma; Humans; Male; Middl | 2022 |
Effects of modafinil and caffeine on night-time vigilance of air force crewmembers: A randomized controlled trial.
Topics: Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Hum | 2023 |
Effects of modafinil and caffeine on night-time vigilance of air force crewmembers: A randomized controlled trial.
Topics: Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Hum | 2023 |
Effects of modafinil and caffeine on night-time vigilance of air force crewmembers: A randomized controlled trial.
Topics: Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Hum | 2023 |
Effects of modafinil and caffeine on night-time vigilance of air force crewmembers: A randomized controlled trial.
Topics: Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Hum | 2023 |
A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the "COMBO-MS" trial.
Topics: Central Nervous System Stimulants; Cognitive Behavioral Therapy; Combined Modality Therapy; Fatigue; | 2019 |
Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine.
Topics: Adult; Attention; Caffeine; Central Nervous System Stimulants; Cognition; Double-Blind Method; Fatig | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study.
Topics: Administration, Oral; Adult; Aged; Dexamethasone; Double-Blind Method; Fatigue; Female; Follow-Up St | 2021 |
Double-Blind, Placebo-Controlled, Crossover Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia.
Topics: Benzhydryl Compounds; Cross-Over Studies; Double-Blind Method; Fatigue; Female; Humans; Male; Middle | 2017 |
MIDAS (Modafinil in Debilitating Fatigue After Stroke): A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cross-Over Studies; Double-Blind Method; Fatigue; Fem | 2017 |
Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Docetaxel; Double-Blind Method; Fatigue; Humans; Male | 2017 |
Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial.
Topics: Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Fatigue; Hum | 2018 |
Predicting Modafinil-Treatment Response in Poststroke Fatigue Using Brain Morphometry and Functional Connectivity.
Topics: Adult; Aged; Brain; Caudate Nucleus; Cohort Studies; Cross-Over Studies; Double-Blind Method; Fatigu | 2019 |
Modafinil treatment modulates functional connectivity in stroke survivors with severe fatigue.
Topics: Brain Mapping; Central Nervous System Stimulants; Connectome; Double-Blind Method; Fatigue; Female; | 2019 |
The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Brain Neoplasms; Cognition Disorders; Cross-Ov | 2013 |
Effect of armodafinil on cognition in patients with HIV/AIDS and fatigue.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Benzhydryl Compounds; CD4 Lymphocyte Count; Central | 2013 |
Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study.
Topics: Acetylcarnitine; Adult; Amantadine; Benzhydryl Compounds; Drug Combinations; Fatigue; Female; Humans | 2013 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Doceta | 2014 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Doceta | 2014 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Doceta | 2014 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Doceta | 2014 |
Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Carcinoma, Non-Small-Cell Lung; Central Nervous Syste | 2014 |
A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.
Topics: Adult; Aged; Benzhydryl Compounds; Cross-Over Studies; Double-Blind Method; Fatigue; Female; Humans; | 2015 |
Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue.
Topics: Adult; Aged; Benzhydryl Compounds; Brain Neoplasms; Double-Blind Method; Fatigue; Female; Glioblasto | 2015 |
Armodafinil for fatigue associated with menopause: an open-label trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; | 2016 |
Structured cues or modafinil for fatigue amelioration in clinicians? A double-blind, randomized controlled trial of critical clinical information recall in fatigued clinicians.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cues; Double-Blind Method; Drug Administration Schedule; Fa | 2016 |
Modafinil May Alleviate Poststroke Fatigue: A Randomized, Placebo-Controlled, Double-Blinded Trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Double-Blind Method; Fatigue; Female; Humans; Male; M | 2015 |
Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial.
Topics: Benzhydryl Compounds; Cognitive Behavioral Therapy; Combined Modality Therapy; Fatigue; Female; Foll | 2016 |
Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial.
Topics: Adult; Benzhydryl Compounds; Cognition; Cognition Disorders; Cross-Over Studies; Double-Blind Method | 2016 |
Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Depression; Double-Blind Method; F | 2016 |
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Double-Blind Method; Fatigue; Female; Glioma; | 2016 |
Modafinil In Debilitating fatigue After Stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-controlled, crossover trial.
Topics: Affect; Benzhydryl Compounds; Clinical Protocols; Cognition; Cross-Over Studies; Double-Blind Method | 2016 |
Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Benzhydryl Compounds; Central Nervous | 2009 |
Modafinil for the treatment of fatigue in lung cancer: a pilot study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Carcinoma, Non-Small-Cell Lung; Central Nervous Syste | 2009 |
The effect of modafinil on cognitive function in breast cancer survivors.
Topics: Adult; Aged; Aged, 80 and over; Attention; Benzhydryl Compounds; Breast Neoplasms; Cognition; Fatigu | 2009 |
Modafinil effects in multiple sclerosis patients with fatigue.
Topics: Adult; Analysis of Variance; Attention; Benzhydryl Compounds; Double-Blind Method; Evoked Potentials | 2009 |
A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue.
Topics: Activities of Daily Living; Affect; Benzhydryl Compounds; Central Nervous System Stimulants; Drug-Re | 2009 |
Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial.
Topics: Adult; Aged; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders | 2009 |
Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Cl | 2009 |
Modafinil reduces patient-reported tiredness after sedation/analgesia but does not improve patient psychomotor skills.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia; Anesthesia Recovery Period; Anesthetics, Inha | 2010 |
Modafinil effects on cognitive function in HIV+ patients treated for fatigue: a placebo controlled study.
Topics: Adult; Aged; Analysis of Variance; Benzhydryl Compounds; CD4 Antigens; Central Nervous System Stimul | 2010 |
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L | 2010 |
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L | 2010 |
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L | 2010 |
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L | 2010 |
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner | 2010 |
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner | 2010 |
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner | 2010 |
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner | 2010 |
Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury.
Topics: Adult; Aged; Benzhydryl Compounds; Brain Injuries; Disorders of Excessive Somnolence; Double-Blind M | 2010 |
Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Female; H | 2011 |
HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis.
Topics: Adult; Benzhydryl Compounds; Double-Blind Method; Fatigue; Female; Humans; Male; Modafinil; Multiple | 2011 |
A single dose of armodafinil significantly promotes vigilance 11 hours post-dose.
Topics: Adolescent; Adult; Aerospace Medicine; Arousal; Attention; Benzhydryl Compounds; Central Nervous Sys | 2011 |
Modafinil as a replacement for dextroamphetamine for sustaining alertness in military helicopter pilots.
Topics: Adult; Aerospace Medicine; Aircraft; Arousal; Benzhydryl Compounds; Central Nervous System Stimulant | 2012 |
Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil.
Topics: Adult; Arousal; Autonomic Nervous System; Benzhydryl Compounds; Cardiovascular Agents; Central Nervo | 2013 |
Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Cross-Over Studies; Dose-Response Re | 2013 |
Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study.
Topics: Adult; Benzhydryl Compounds; Cognition; Cognition Disorders; Cross-Over Studies; Double-Blind Method | 2012 |
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Di | 2003 |
Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy.
Topics: Adolescent; Adult; Affect; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Dose-Respo | 2004 |
A prospective trial of modafinil as an adjunctive treatment of major depression.
Topics: Adult; Aged; Antidepressive Agents; Benzhydryl Compounds; Depressive Disorder, Major; Diagnostic and | 2004 |
Modafinil improves recovery after general anesthesia.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Anesthesia, Gen | 2004 |
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2004 |
Effects of modafinil on cognitive and meta-cognitive performance.
Topics: Adolescent; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition; Double-Blind | 2004 |
An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder; Diagnostic and | 2004 |
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys | 2004 |
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys | 2004 |
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys | 2004 |
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys | 2004 |
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.
Topics: Adult; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition; Cognition Diso | 2005 |
Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Human | 2006 |
Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2006 |
Prior sleep with zolpidem enhances the effect of caffeine or modafinil during 18 hours continuous work.
Topics: Adult; Aerospace Medicine; Attention; Benzhydryl Compounds; Caffeine; Central Nervous System Stimula | 2006 |
Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Attention; Benzhydryl Compounds; Central Nervous System Stimul | 2007 |
An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis.
Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnole | 2007 |
Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Central Nervous System Stimulants; Cross-Over Studies | 2007 |
Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2007 |
Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Agents; Fatigue; Female; Human | 2002 |
Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Agents; Fatigue; Female; Human | 2002 |
Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Agents; Fatigue; Female; Human | 2002 |
Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Agents; Fatigue; Female; Human | 2002 |
60 other studies available for modafinil and Fatigue
| Article | Year |
|---|---|
Subjective Effects of Modafinil in Military Fighter Pilots During Deployment.
Topics: Aerospace Medicine; Caffeine; Fatigue; Humans; Military Personnel; Modafinil; Pharmaceutical Prepara | 2022 |
Returning to work after fatigue treatment and counseling in HIV/AIDS.
Topics: Adult; Behavior Therapy; Counseling; Fatigue; Female; HIV Infections; Humans; Male; Middle Aged; Mod | 2019 |
Modafinil in Recovery after Stroke (MIRAS): A Retrospective Study.
Topics: Aged; Aged, 80 and over; Central Nervous System Stimulants; Disability Evaluation; Fatigue; Female; | 2020 |
Vigilance Aid Use and Aircraft Carrier Landing Performance in Pilots of Tactical Aircraft.
Topics: Aerospace Medicine; Aircraft; Fatigue; Humans; Military Medicine; Modafinil; Pilots; Retrospective S | 2020 |
Exploring the Economic Benefits of Modafinil for Post-Stroke Fatigue in Australia: A Cost-Effectiveness Evaluation.
Topics: Aged; Australia; Central Nervous System Stimulants; Clinical Trials, Phase II as Topic; Cost Savings | 2020 |
Are drugs for multiple sclerosis fatigue just placebos?
Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Methylphenidate; Modafinil; Multiple Sclerosis; Ph | 2021 |
Improvement of lupus-associated fatigue with modafinil: Report of two cases.
Topics: Fatigue; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Modafinil; Quality of Life; Sev | 2021 |
Modafinil as a Stimulant for Military Aviators.
Topics: Accidents, Aviation; Adult; Aerospace Medicine; Anxiety; Central Nervous System Stimulants; Diarrhea | 2019 |
Tako-tsubo cardiomyopathy following modafinil use.
Topics: Aged; Benzhydryl Compounds; Fatigue; Female; Follow-Up Studies; Humans; Modafinil; Takotsubo Cardiom | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
A clinically translatable mouse model for chemotherapy-related fatigue.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Benzhydryl Compounds; Disease Models, Animal; Doxo | 2013 |
Laying to rest psychostimulants for cancer-related fatigue?
Topics: Benzhydryl Compounds; Carcinoma, Non-Small-Cell Lung; Central Nervous System Stimulants; Fatigue; Fe | 2014 |
Survivorship: cognitive function, version 1.2014.
Topics: Adaptation, Psychological; Benzhydryl Compounds; Brain Neoplasms; Central Nervous System Stimulants; | 2014 |
OBLIGING SURGEONS TO ENHANCE: NEGLIGENCE LIABILITY FOR UNCORRECTED FATIGUE AND PROBLEMS WITH PROVING CAUSATION.
Topics: Benzhydryl Compounds; Fatigue; Humans; Liability, Legal; Modafinil; Self Administration; Surgeons; U | 2015 |
The Use of Modafinil in the Intensive Care Unit.
Topics: Aged; Benzhydryl Compounds; Critical Care; Disorders of Excessive Somnolence; Fatigue; Humans; Inten | 2016 |
Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Case-Control Studie | 2015 |
Ethical use of cogniceuticals in the militaries of democratic nations.
Topics: Benzhydryl Compounds; Caffeine; Canada; Central Nervous System Stimulants; Cognition; Cross-Cultural | 2008 |
Cancer investigators make strides in improving patients' quality of life.
Topics: Acupuncture Therapy; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Modaf | 2008 |
No rest for fatigue researchers.
Topics: Activities of Daily Living; Anemia; Antineoplastic Agents; Benzhydryl Compounds; Central Nervous Sys | 2008 |
Acceleration tolerance at night with acute fatigue and stimulants.
Topics: Acceleration; Adaptation, Physiological; Adult; Aerospace Medicine; Amphetamine; Analysis of Varianc | 2008 |
Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience.
Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Female; Follow-Up Stu | 2009 |
Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fa | 2009 |
Modafinil for multiple sclerosis fatigue: does it work?
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Female; Follow-Up Studies; | 2010 |
Fatigue, countermeasures, and performance enhancement in resident physicians.
Topics: Academic Medical Centers; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Fati | 2009 |
Preliminary observations suggesting that treatment with modafinil improves fatigue in patients with orthostatic intolerance.
Topics: Activities of Daily Living; Adolescent; Adult; Benzhydryl Compounds; Central Nervous System Stimulan | 2011 |
Modafinil use in patients with a primary psychiatric illness.
Topics: Adult; Affect; Arousal; Benzhydryl Compounds; Bipolar Disorder; Brain Injury, Chronic; Central Nervo | 2010 |
A follow-up study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Fatigue; | 2010 |
Fatigue and stimulant use in military fighter aircrew during combat operations.
Topics: Adult; Aerospace Medicine; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Circad | 2010 |
[Modafinil for the treatment of cancer-related fatigue : an intervention study].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Central Nervous Sy | 2010 |
Modafinil is not the new caffeine.
Topics: Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Dose-Response Relationship, Drug; | 2010 |
Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe.
Topics: Amitriptyline; Amyotrophic Lateral Sclerosis; Benzhydryl Compounds; Cognition Disorders; Community N | 2011 |
Reining in the pharmacological enhancement train: we should remain vigilant about regulatory standards for prescribing controlled substances.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognition; Drug and Narcotic Control; Drug | 2011 |
Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study.
Topics: Adult; Anxiety; Benzhydryl Compounds; Central Nervous System Stimulants; Dizziness; Fatigue; Female; | 2002 |
You'll lose sleep over this pill.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Doping in Sports; Fatigue; Humans; Modafini | 2003 |
[Effects of modafinil on visual and auditory reaction abilities and subjective fatigue level during 48 h sleep deprivation].
Topics: Adolescent; Adult; Attention; Auditory Perception; Benzhydryl Compounds; Central Nervous System Stim | 2003 |
Modafinil vs. caffeine: effects on fatigue during sleep deprivation.
Topics: Adolescent; Adult; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Dose-Response | 2004 |
Modafinil for the treatment of pain-associated fatigue: review and case report.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Chronic Disease; Fatigue; Female; Hu | 2004 |
Modafinil augmentation of phenelzine for residual fatigue in dysthymia.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Comorbidity; Disorders of Excessive Somnole | 2004 |
Modafinil's effects on simulator performance and mood in pilots during 37 h without sleep.
Topics: Adult; Affect; Aviation; Benzhydryl Compounds; Central Nervous System Stimulants; Computer Simulatio | 2004 |
[Modafinil and fatigue in multiple sclerosis].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Fatigue; Humans; | 2004 |
Does modafinil improve recovery?
Topics: Anesthesia Recovery Period; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans | 2004 |
Dr. Makela replies to Dr. Berigan.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Modafinil; Sleep Wake Disorders | 2004 |
Psychostimulants and G tolerance in rhesus monkeys: effects of oral modafinil and injected caffeine.
Topics: Acceleration; Aerospace Medicine; Animals; Benzhydryl Compounds; Caffeine; Central Nervous System St | 2005 |
Treating fatigue in patients with MS: one step forward, one step back.
Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants | 2005 |
Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures.
Topics: Acetamides; Aerospace Medicine; Anti-Anxiety Agents; Benzhydryl Compounds; Circadian Rhythm; Fatigue | 2005 |
A case of premature ventricular contractions with modafinil.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders; Drug Administration Sc | 2005 |
Modafinil for the treatment of fatigue in primary biliary cirrhosis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Female; Humans; Liver Cirrhosis, B | 2005 |
[Fatigue and episodic exhaustion as a feature of multiple sclerosis].
Topics: 4-Aminopyridine; Amantadine; Amifampridine; Benzhydryl Compounds; Fatigue; Humans; Hypnotics and Sed | 2006 |
Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Central Nervous System Stimulants; Drug Tolera | 2006 |
Treatment of fatigue: modafinil, methylphenidate, and goals of care.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Female; Germany; Humans; Me | 2006 |
P300 and treatment effect of modafinil on fatigue in multiple sclerosis.
Topics: Acoustic Stimulation; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Electroencepha | 2007 |
Medicinal studies in palliative care: impact of the EU clinical trials directive.
Topics: Benzhydryl Compounds; Biomedical Research; Central Nervous System Stimulants; Clinical Trials as Top | 2007 |
Modafinil treatment for fatigue associated with fibromyalgia.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Fibromyalgia; Humans; Middle Aged; | 2007 |
Modafinil's use in combating interferon-induced fatigue.
Topics: Aged; Antiviral Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depression; Fatigue | 2007 |
Modafinil improves primary nocturnal enuresis in multiple sclerosis.
Topics: Adult; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants; Fatigue; Fem | 2007 |
Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS).
Topics: Adolescent; Adult; Aged; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Dopami | 2007 |
Low dose of alertness drug counters 'family fatigue'.
Topics: Aged; Attention; Benzhydryl Compounds; Child; Competitive Behavior; Family Health; Fatigue; Female; | 2008 |
Re: Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Comorbidity; Diagnosis, Differential; Fatig | 2008 |
["Fatigue" in multiple sclerosis].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Dose-Response Rel | 2000 |
Modafinil for fatigue in multiple sclerosis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials, Phase II as Topic; Fatigue | 2002 |